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Zusammenfassung
Der Fibroblasten Wachstumsfaktor 23 (FGF23) wird vom Knochen sezerniert und gelangt
u¨ber die Blutgefa¨sse in die Nieren, in welchen er die Phosphatkonzentration des Blutes
und den Vitamin D3 Metabolismus reguliert. Patienten im 2. und 3. Stadium der chronis-
chen Nierenerkrankung (CKD) haben erho¨hte FGF23 Blutwerte, welche im Endstadium
von CKD wesentlich zu kardiovaskula¨ren Komplikationen und zur erho¨hten Sterblichkeit
beitragen. Die polyzystische Nierenerkrankung (ADPKD) fu¨hrt zu CKD, wobei jedoch
erho¨hte FGF23 Blutwerte bereits bei normaler Nierenfunktion vorliegen. Die Regulierung
von FGF23 in ADPKD und CKD ist zu weiten Teilen unbekannt. In dieser Studie wur-
den PKD Tiermodelle verwendet um die Regulation von FGF23 in CKD zu untersuchen.
Fgf23 war in PKD Ratten, a¨hnlich wie bei ADPKD Patienten, erho¨ht bevor die Nieren-
funktion abnahm. Trotz erho¨hter Fgf23 Blutwerte waren keine Vera¨nderungen in Bezug
auf die Phosphat- oder die Vitamin D3 Konzentrationen im Blut zu beobachten. Die
Signalkaskade, welche von Fgf23 in der Niere ausgelo¨st wird, war intakt. Daraus geht
hervor, dass die Nieren von PKD Ratten resistent gegenu¨ber Fgf23 sind. Wir zeigten,
dass die Fgf23 Expression in PKD Ratten und Ma¨usen statt im Knochen in der Niere
erho¨ht war. Anschliessend evaluierten wir Sauerstoffarmut oder Entzu¨ndungsfaktoren als
zwei mo¨gliche Ursachen, welche die Regulation der Fgf23 Expression in der Niere und im
Knochen beeinflussen. In prima¨ren Mausosteozyten erho¨hte der Entzu¨ndungsfaktor Tu-
mornekrosefaktor (Tnfα), nicht aber die Sauerstoffarmut, die Fgf23 Expression. In PKD
Nieren war die Tnfα Expression erho¨ht und zusa¨tzlich begleitet von einer erho¨hten Expres-
sion des nukla¨ren Rezeptors Nurr1. Nurr1 stimuliert Fgf23 Expression im Knochen. Die
Blockierung von Tnfα in PKD Ma¨usen resultierte in der Reduktion der Fgf23 Blutwerte
sowie der Reduktion der renalen Fgf23 und Nurr1 Expression. Mit dieser Studie kon-
nten wir aufzeigen, dass der Entzu¨ndungsfaktor Tnfα eine wichtige Rolle spielt in der
Regulation von Fgf23 Expression in der Niere und im Knochen.
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Abstract
Fibroblast growth factor 23 (FGF23) is a bone derived endocrine factor which regulates
phosphate homeostasis and vitamin D3 metabolism in the kidney. FGF23 rises in chronic
kidney disease (CKD) stage G2 to G3 and contributes significantly to cardiovascular dis-
ease and all cause mortality in endstage renal disease. Autosomal dominant polycystic
kidney disease (ADPKD) is a cause for CKD where the increase in FGF23 precedes the first
measurable decline in renal function. The mechanisms governing FGF23 production and
effects in kidney disease are largely unknown. In this study we investigated the regulation
of Fgf23 in PKD using the Han:SPRD rat and Pkd1 conditional KO mouse model. We
found highly elevated Fgf23 levels in Han:SPRD cy/+ rats while renal function was still
normal. Despite the high Fgf23 levels, phosphate handling and vitamin D3 metabolism
were unchanged and the Fgf23 signaling cascade was intact indicating resistance to Fgf23.
We evaluated the source of Fgf23 and found that Fgf23 expression in kidney but not in
bone was increased. In PKD kidneys, the cells lining the cysts expressed Fgf23. This
triggered the question of the regulation of Fgf23 expression in bone and de novo Fgf23
expression in kidney. We investigated the effect of hypoxia and the inflammatory cytokine
Tnfα on Fgf23 expression in bone cells. Tnfα but not hypoxia regulated Fgf23 expression
in primary mouse osteocytes. In PKD kidneys, elevated Tnfα and Tgfβ expression levels
were paralleled by increased expression of the orphan nuclear receptor Nurr1. Nurr1 is
involved in the Pth dependent upregulation of Fgf23 in bone. In PKD kidneys, Nurr1 was
predominantly localized in the nucleus and often overlapped with Fgf23 protein expres-
sion. Neutralization of Tnfα reduced Fgf23 plasma levels in PKD and healthy animals
and decreased the renal expression of inflammatory cytokines. Furthermore application
of anti-Tnfα antibodies tended to result in lower renal Fgf23 and Nurr1 expression. This
study provides strong evidence that the inflammatory cytokine Tnfα modulates Fgf23
expression in cystic kidneys as well as in osteocytes.
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Chapter 1
Introduction
1.1 The biological function of phosphorus
Phosphorus is a key element in various biological processes such as energy production,
cell signaling, mineralization of the endoskeleton as well as membrane and protein synthe-
sis [1–6]. In a balanced diet, humans consume daily approximately 20 mg/kg phosphorus
from which 16 mg/kg is absorbed by the intestine [7]. The pancreas as well as the intestine
secret 3 mg/kg phosphorus into the intestine in the form of digestive juice that results in
a daily net phosphorus absorption into the circulation of 13 mg/kg and net phosphorus
excretion into the feces of 7 mg/kg [7]. Additionally, there is a constant bone turnover
which amounts to 3 mgkg∗day [7]. In mammals, phosphorus occurs in the form of mono- or
divalent inorganic phosphate (Pi) (H2PO4
− and HPO42−) or organic phosphates which are
combinations of phosphate and lipids, carbohydrates, or proteins [8]. The average plasma
Pi concentration in children is between 1.3 and 2.3 mmol/l and in adults between 0.8 and
1.5 mmol/l [8, 9]. The high extracellular Pi concentration in young mammals is important
for normal growth and bone mineralization [9, 10]. In adults 80-90 % of phosphate is
found in the form of hydroxyapatite in bone and 9% in the form of organic phosphate
in skeletal muscle [4, 5, 8]. Phosphate which is not deposited in bone is mostly localized
intracellularly in the form of organic phosphate and to a minor fraction in the form of Pi
[8]. With an estimated concentration of up to 100 mmol/l, Pi is the main intracellular
anion [8].
Disturbances of phosphate homeostasis lead to severe physiological problems. An acute
negative phosphate balance causes leukocyte and erythrocyte dysfunction due to impair-
ment of ATP synthesis as well as altered cardiac function and myopathy [8, 11, 12]. Chronic
3
phosphate deficiency results in impaired bone mineralization and therefore causes rickets
and osteomalcia [13, 14]. On the other hand hyperphosphatemia leads to ectopic calcifica-
tion of soft tissues and vasculature which in turn causes inflammation and cardiovascular
disease [15, 16]. An acute and severe increase of serum phosphate levels is accompanied
by a drop in the serum calcium concentration which leads to tetany [17]. To prevent un-
balanced phosphate homeostasis plasma Pi is tightly regulated by intestinal absorption,
renal excretion and bone turnover [18–20]. In this organ orchestra, hormones adjust serum
phosphate levels mainly by regulating phosphate reabsorption in the kidney.
Figure 1.1: Quantitative phosphate homeostasis in humans. Intestine and kidneys are
the main organs regulating phosphate absorption and excretion in the human body. Bone is in
absolute need of phosphate to maintain its structural integrity and serves at the same time as an
internal phosphate storage pool. Adapted from Berndt et al. (2007) [6].
1.2 Phosphate reabsorption in the kidney by sodium-depen-
dent phosphate co-transporters
Phosphate reabsorption in the kidney takes place along the proximal tubule where sodium-
dependent phosphate co-transporters NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3) of the
SLC34 family as well as PiT-2 of the SLC20 family are responsible for phosphate reabsorp-
tion at the apical membrane of proximal tubule epithelia [21–26]. NaPi-IIa is expressed
along the entire proximal tubule whereas NaPi-IIc and PiT-2 are predominantly expressed
in the S1 segment [26–28]. Both SLC34 members transport divalent Pi (HPO4
2−) but with
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a different stoichiometry: NaPi-IIa is electrogenic and transports 1Pi:3Na+ and NaPi-IIc
is electroneutral and transports 1Pi:2Na+ [29]. PiT-2 transports monovalent Pi (H2PO4
−)
with a ratio of 1Pi:2Na+ (Figure 1.2) [29]. The sodium gradient for the secondary active
sodium-dependent phosphate co-transport is maintained by the Na-K-ATPase which is
localized at the basolateral side of proximal tubule cells [30]. The exit pathway for Pi at
the basolateral side is so far unknown (Figure 1.2).
The importance of NaPi-IIa and NaPi-IIc in terms of phosphate transport in the kid-
ney depends on the species [31]. Human mutations of SLC34A3 (NaPi-IIc) gene cause
hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and human mutations
of SLC34A1 (NaPi-IIa) gene lead to idiopathic infantile hypercalcemia which is charac-
terized by primary renal phosphate wasting and hypercalcemia [31–34]. This suggests
that both NaPi-IIa and NaPi-IIc play an important role in human phosphate homeostasis
[31]. NaPi-IIc−/− as well as kidney specific conditional NaPi-IIc KO mice have similar
plasma phosphate levels and display normal bone growth compared with wild type animals
[35, 36]. In contrast, mice lacking NaPi-IIa display hypophosphatemia but surprisingly
they do not suffer from hypophosphatemic rickets [31, 37]. NaPi-IIa−/− and NaPi-IIc−/−
double KO animals suffer from severe hypophosphatemia accompanied by rickets which
is similar to the HHRH phenotype in humans [31, 38]. High Pi diet can rescue both
HHRH and NaPi-IIa−/−, NaPi-IIc−/− double KO mice phenotypes [31, 38]. These find-
ings propose that NaPi-IIc in mice is less important in mediating phosphate homeostasis
compared to NaPi-IIc in humans [31]. Due to the fact that NaPi-IIc is not able to rescue
the hypophosphatemic phenotype in NaPi-IIa−/− mice, NaPi-IIa plays a more important
role in phosphate homeostasis compared to NaPi-IIc [31]. But nevertheless there is a
synergism between NaPi-IIa and NaPi-IIc because loss of both proteins is necessary to
cause severe hypophosphatemia and rickets in mice [31]. The importance of NaPi-IIa in
mice is also reflected by the phosphate transport activity in the kidney. NaPi-IIa accounts
for approximately 70% and NaPi-IIc for 30% of phosphate transport activity in mouse
kidneys [25, 37].
The abundance of NaPi-IIa protein at the brush border membrane determines the rate of
renal phosphate reabsorption [39]. Hence, the protein can be regulated at the biosynthe-
sis level, the rate of insertion into the apical membrane, or by endocytotic retrieval from
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the membrane [39]. Currently, the endocytotic regulation process is the most examined
one [39]. It has been shown that receptor mediated endocytosis of NaPi-IIa including
clathrin-coated vesicles, early and late endosomes and lysosomal degradation is an impor-
tant process to reduce its abundance on the brush border membrane [39, 40]. Sodium
hydrogen exchanger regulatory factor 1 (NHERF1) interacts with the c-terminal PDZ
binding motif of NaPi-IIa [41, 42]. Phosphorylation of NHERF1 protein leads to disso-
ciation of the NaPi-IIa-NHERF1 complex and to endocytotic retrieval of NaPi-IIa from
the apical membrane [41]. Dietary phosphate intake, parathyroid hormone (PTH), and
fibroblast growth factor 23 (FGF23) are key regulators of phosphate homeostasis and are
able to modulate abundance of NaPi co-transporter mRNA and protein levels [43–45].
The interplay of these mediators is discussed in the following section.
Figure 1.2: Concept of phosphate reabsorption. Phosphate reabsorption by sodium-
dependent phosphate cotransporter PiT-2, NaPi-IIa, and NaPi-IIc takes place at the brush border
membrane of proximal tubule epithelia. On the basolateral side the Na-K-ATPase maintains the
Na+ gradient which enables the phosphate transport. The exit mechanism of phosphate on the
basolateral side is unknown. Adapted from Biber et al. (2013) [30].
1.3 Hormonal regulation of phosphate homeostasis
PTH, 1,25(OH)2 vitamin D3, FGF23 and Klotho build an endocrine network that tightly
regulates phosphate homeostasis (Figure 1.3) [46]. In this section I will discuss the role of
PTH and vitamin D3 in phosphate homeostasis whereas FGF23 and Klotho are explained
in more detail in the following section.
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The parathyroid gland primarily functions as a calciostat and releases in response to low
calcium levels PTH into the circulation [47]. In addition to calcium, PTH governs serum
phosphate levels mainly by the regulation of phosphate transporters in the proximal tubule
[44, 48]. Oral phosphate loading in humans leads within 45 minutes to increased serum
PTH levels [48]. In the kidney, PTH activates the PTH receptor (PTHR), a G-protein
coupled receptor, which leads to the activation of protein kinase A (PKA) and protein
kinase C (PKC) and the subsequent internalization of sodium phosphate co-transporters
[41, 44, 49]. Phosphorylation-deficient PTHR causes a sustained increase in cAMP pro-
duction and therefore PKA is constitutively activated which leads in mice to permanent
reduction of serum phosphate levels [50]. PTH−/− KO animals suffer from abnormal bone
development, renal calcium loss, and phosphate retention as well as reduced 1,25(OH)2
vitamin D3 and FGF23 levels [47, 51, 52]. 1,25(OH)2 vitamin D3 is the activated form of
vitamin D3 and is metabolized in the kidney [47]. The production of 1,25(OH)2 vitamin
D3 is regulated by the expression and activity of Cyp27b1 and Cyp24a1 which encode
the 1α-hydroxylase (vitamin D3 activating enzyme) and the 24-hydroxlyase (vitamin D3
inactivating enzyme), respectively [47]. In PTH−/−/Hyp double KO animals, exogenous
PTH stimulates 1,25(OH)2 vitamin D3 production independently of FGF23 [52]. In these
mice the expression of Cyp27b1 is completely abolished while the Cyp24a1 expression is
significantly increased compared with Hyp mice (a mouse model of FGF23 excess) [52].
In return, PTH supplementation of PTH−/−/Hyp double KO animals increases Cyp27b1
expression and reduces Cyp24a1 expression [52]. Taken all together, PTH promotes cal-
cium retention and phosphate excretion in the kidney and stimulates 1,25(OH)2 vitamin
D3 production in the kidney and FGF23 expression in bone (Figure 1.3) [46].
The main function of 1,25(OH)2 vitamin D3 is the regulation of bone and mineral metabolism
but it is also involved in other biological processes such as macrophage differentiation and
modification of T-lymphocyte activity [53]. 1,25(OH)2 vitamin D3 mainly acts through
the vitamin D receptor (VDR) which is expressed in many tissues, among them kidney,
intestine, bone, and parathyroid gland [53]. VDR is a cytoplasmic protein and is upon
1,25(OH)2 vitamin D3 activation translocated to the nucleus where it binds to the retinoid
X receptor (RXR) [47, 54, 55]. Within the nucleus the 1,25(OH)2 vitamin D3/VDR-
RXR complex regulates gene expression by binding to vitamin D response elements [56].
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VDR−/− KO animals have a shortened life span and display extremely low serum phos-
phate and FGF23 levels whereas PTH and 1,25(OH)2 vitamin D3 are elevated [57]. The
PTH gene promoter has a vitamin D response element. Binding of the 1,25(OH)2 vitamin
D3/VDR-RXR complex to the vitamin D response element suppresses PTH expression
[58]. Further 1,25(OH)2 vitamin D3 increases dietary phosphate reabsorption in the in-
testine [47]. Overall 1,25(OH)2 vitamin D3 increases serum phosphate levels [47].
Figure 1.3: Endocrine regulation of phosphate metabolism. The principle regulators of
phosphate homeostasis FGF23, PTH, vitamin D and soluble Klotho are regulating each other by
multiple negative feedback loops to tightly regulate phosphate serum levels. Adapted from Hu et
al. (2013) [46].
1.4 Fibroblast growth factor 23 (FGF23)
Within the large fibroblast growth factor super family, FGF23 belongs together with
FGF15/19 and FGF21 to the fibroblast growth factor subfamily 19 [59, 60]. The members
of this family are missing a heparin binding sequence and function therefore as endocrine
factors [60]. FGF15/19 and FGF21 play a unique role in energy and bile acid homeostasis
as well as glucose and lipid metabolism whereas FGF23 is a key player in the regulation
of mineral homeostasis and vitamin D3 metabolism [61, 62]. Human FGF23 is localized
on chromosome 12p13 and encodes FGF23, a secreted, glycosylated 32kDa protein, which
consists of 251 amino acids [59]. The homologue mouse gene shares 72% amino acid
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identity with human FGF23 and lies on chromosome 6 [59]. The promoter region of
human, mouse, and rat FGF23 is highly conserved and has several putative binding sites,
among them a vitamin D3 responsive element [63]. The protein consists of a hydrophobic
signaling sequence, a N-terminal FGF homology region and a C-terminal receptor binding
region (see Figure 1.4) [46, 59, 64]. FGF23 is mainly expressed in bone and to a much
lower extend in thymus, brain, and heart [59, 61, 62, 65].
 Intact FGF23 32-35 kDa 
 ♦ SPC processing site 
 Glycosylation side 
N-terminal FGF 
homology region 
15-18 kDa 
C-terminal receptor 
binding region 
12-15 kDa 
Signal 
peptide 
1 24 25 175 180 251 
176RHTR179 
T171 S180 T200 
Figure 1.4: Schematic structure of the intact FGF23 protein. Signal peptide (grey) tags
FGF23 as a secreted protein, N-terminal FGF homology region (blue), and C-terminal receptor
binding region (green). The amino sequence 176RHTR179 is a subtilisin-like proprotein convertase
(SPC) cleavage site where FGF23 can be processed in an inactive C- and N-terminal fragment.
Adapted from Hu et al. (2013) and Bhattacharyya et al. (2012). [46, 64, 66]
1.4.1 FGF23-FGF receptor (FGFR)-Klotho complex
Four FGFR genes (FGFR1-FGFR4 ) encode seven different receptor tyrosin kinases [60].
FGFR receptors are structured in an extracellular ligand-binding domain with three im-
munoglobulin domains, a transmembrane domain, and an intracellular tyrosine kinase
domain [60]. Alternative splicing of the FGFR1-3 immunoglobulin domains generates
two proteins (e.g. FGFR1b and FGFR1c) with different ligand-binding specificity [60].
FGFR receptors are widely expressed all over the body and as FGF signaling is mostly
autocrine and paracrine the local FGF expression set determines the degree of signaling
[62]. The binding of FGF-FGFR needs heparan sulfate (HS), a polysaccarid with variably
sulfated repeating disaccharide units [67]. HS is structurally similar to heparin which can
replace HS in the FGF-FGFR complex formation [67]. Heparin or HS interacts with its
nonreducing ends with both FGF and FGFR which leads to the formation of a stable
1:1:1 FGF:FGFR:heparin ternary complex [68]. For receptor dimerization the recruitment
of a second FGF:FGFR:heparin/HS ternary complex is necessary and is initiated either
by direct FGFR:FGFR contacts or by secondary interaction between FGF of one ternary
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complex with FGFR in the other ternary complex or by indirect heparin/HS mediated
FGFR-FGFR contacts [68]. As mentioned in the previous section, FGF23 is an endocrine
factor and distinguished from the other auto- and paracrine acting FGFs by the altered
heparin binding sequence (HBS) [67]. The HBS of FGF23 has a very poor binding affin-
ity to HS and thus the pericellular HS is neither able to trap and immobilize FGF23 in
the extracellular matrix nor form the necessary complex with FGFR for signal transduc-
tion [67]. Consequently, FGF23 has an endocrine mode of action and needs the co-ligand
Klotho for FGFR signaling whose expression pattern determines the FGF23 target organs
[69]. Klotho was originally discovered as a gene which prevents premature aging and is
mainly expressed in kidney and brain and to a lower extend in pituitary, placenta, skeletal
muscle, urinary bladder, aorta, pancreas, testis, ovary, colon and thyroid gland [70]. In
mouse and human, Klotho encodes either a single transmembrane or by alternative splic-
ing a shortened secreted protein [71, 72]. The membrane-bound Klotho protein consists of
a short N-terminal signaling sequence, an extracellular domain with two internal repeats
(KL1 and KL2), a single transmembrane domain and a short intracellular domain [72].
The extracellular domain of membrane Klotho can be shed by the two metalloproteases
ADAM10 and ADAM17 in a 68kDa (KL1) or a 130kDa (KL1+KL2) fragment [73]. Klotho
is essential for FGF23 signaling through FGFR receptors and therefore its expression de-
terminates the target organs of FGF23 [69, 74]. In immunoprecipitation experiments it
has been shown that Klotho binds most of the FGFR receptor isoforms but nevertheless
the affinity of Klotho with FGFR c isoforms is much stronger compared to b isoforms [74].
Further FGFR2 has a lower affinity for interaction with Klotho compared with FGFR1,
FGFR3 and FGFR4 [74]. FGF23 itself does not interact with Klotho or FGFR alone,
it only binds FGFR1c, FGFR3c, and FGFR4 in combination with Klotho [74]. The ne-
cessity of Klotho for FGF23 signaling could also be demonstrated by blocking Klotho in
vivo. The injection of an anti-Klotho antibody in wild type mice leads after 4 hours to
the upregulation of Cyp27b1 and downregulation of Cyp24a1 gene expression followed
after 9 and 24 hours by increasing 1,25(OH)2 vitamin D3, phosphate, and FGF23 serum
concentration [69]. Klotho converts FGFR receptors into a FGF23 responsive receptor
with non-mitogenic character (Figure 1.5) [69].
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P 
P 
P 
P 
Klotho FGFR 
Heparin, 
Heparan sulfate 
Tyrosin Kinase Domain 
Figure 1.5: Schematic illustration of FGF23-Klotho-FGFR receptor complex. Re-
ceptor activation leads to dimerization and cross-phosphorylation of FGFR tyrosine kinase do-
mains and activates the downstream signaling molecules. Downstream signaling occurs mainly
through the MAPK and AKT pathway. FRS2α, fibroblast growth factor receptor substrate 2α;
GRB2, growth factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; PI3K,
phosphoinositide-3 kinase; AKT, v-akt murine thymoma viral oncogene; SOS, son of sevenless;
RAS, rat sarcoma; MAPK, mitogen-activated protein kinase. Adapted from Urakawa et al. (2006)
and Tenhagen et al. (2012) [69, 75].
1.4.2 FGF23 action in the kidney
The high expression levels of Klotho and the presence of several FGFR receptors in the
kidney makes the kidney to the main target organ of FGF23 [70, 76]. It is well estab-
lished that FGF23 in the kidney inhibits phosphate reabsorption and vitamin D3 synthesis
[61, 65, 77–79] but there is growing evidence that FGF23 additionally impacts sodium re-
tention and calcium reabsorption [80, 81]. In this section I will focus on the effects of
FGF23 in the kidney regarding phosphate reabsorption and vitamin D3 metabolism.
FGF23 signaling is dependent on the presence of the Klotho-FGFR receptor complex [69].
In the kidney Klotho is mostly expressed in the distal convoluted tubule and as shown
by several groups to a lower extent in the proximal tubule where phosphate reabsorption
takes place (see section 1.2) [82, 83]. The proximal tubule expresses FGFR1 and FGFR3
as well as FGFR4 but not FGFR2 receptors [84]. FGFR3−/− and FGFR4−/− KO mice
lower the serum phosphate level in response to FGF23 administration, but FGFR1−/−
KO mice do not [84]. This suggests that FGF23 signaling in the proximal tubule happens
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predominantly by binding of FGF23 to the Klotho-FGFR1 receptor complex and FGFR3
and FGFR4 play a minor role [84]. This is further supported by the fact that phosphate
wasting in the Hyp mice, a model of FGF23 excess, is not inhibited by the ablation of
either FGFR3 or FGFR4 receptors [85]. Finally, kidney specific FGFR1−/−/FGFR4−/−
double KO mice have elevated serum phosphate and FGF23 levels and do not respond to
exogenously added FGF23 [86]. Therefore FGFR1 displays a key function in mediating
FGF23 dependent phosphaturia which is supported by FGFR3 and FGFR4 [84–87]. The
binding of FGF23 to the corresponding Klotho-FGFR receptor complex in cultured proxi-
mal tubular cells activates in a dose and time dependent manner the extracellular signaling
regulated kinase (ERK1/2) protein [69, 83]. Downstream of ERK1/2, serum glucocorti-
coid regulated kinase 1 (SGK1) is phosphorylated by P-ERK1/2 which is prevented by
an ERK1/2 inhibitor [83]. Phospho-SGK1 in turn phosphorylates NHERF1 which results
in the internalization and lysosomal degradation of the sodium phosphate co-transporter
NaPi-IIa from the brush border membrane [41, 83]. Lack of Klotho abolishes this process
which proves that the effect of FGF23 on NaPi-IIa internalization is Klotho dependent
[83].
FGF23 decreases plasma concentration of 1,25(OH)2 vitamin D3 by downregulation of 1α-
hydroxylase and upregulation of 24-hydroxylase gene and protein expression in the kidney
[77, 79]. It has been shown that the regulation of vitamin D3 metabolism is dependent
on the MAPK signaling pathway [88–90]. In vitro and in vivo application of the MAPK
inhibitor blocks the effects of FGF23 on the downregulation of 1α-hydroxylase and up-
regulation of 24-hydroxylase [88–90]. Due to high FGF23 serum concentration MAPK
signaling in Hyp mice is constitutively activated [89, 90]. Long term blockade of MAPK
signaling pathways in Hyp mice restores normal 1.25(OH)2 vitamin D3 serum levels [90].
1.4.3 FGF23 action in the parathyroid gland
The parathyroid gland expresses Klotho as well as FGFR1 and FGFR3 which makes the
gland a target organ of FGF23 [91]. Administration of FGF23 in rats for 5 days leads
to an upregulation of Klotho protein and a downregulation of PTH gene expression in
the parathyroid gland as well as decreased serum PTH levels [91]. Short term intravenous
FGF23 administration in rats downregulates serum PTH levels within 10 minutes whereas
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intraperitoneal FGF23 administration needs 40 minutes to downregulate PTH serum and
mRNA levels [91]. The regulation of PTH expression by FGF23 is dependent on MAPK
signaling pathways and therefore is inhibited by an ERK1/2 inhibitor which prevents the
reduction of serum PTH concentration in rats after FGF23 administration [91]. Simi-
larly, cultured bovine parathyroid gland cells are in a dose and time dependent manner
sensitive to FGF23 treatment and are increasing early growth response protein 1 (Egr-1 )
expression within an hour whereas PTH expression is downregulated after 12 hours [92].
Additionally, parathyroid cells treated with FGF23 display a higher Cyp27b1 expression
compared with vehicle treated cells [92]. In rats with chronic kidney disease (CKD) which
was either induced by adenine diet or 5/6 nephrectomy, FGF23 treatment does not acti-
vate ERK1/2 and PTH expression as observed in wild type animals [93, 94]. Further on in
the hyperplastic parathyroid gland of CKD animals Klotho and FGFR1 mRNA and pro-
tein levels are decreased [93, 94]. The absence of the functional FGF23 receptor explains
the observed resistance of the parathyroid gland against FGF23 [93, 94]. The same event
sequence is observed in humans with CKD where hyperplasia of the parathyroid gland is
accompanied by a decrease in Klotho and FGFR1 expression and a subsequent resistance
of the parathryoid against FGF23 [95, 96]. Parathyroid specific deletion of Klotho reveals
a Klotho independent effect of FGF23 on PTH in the parathyroid gland [97]. PTH-KL−/−
mice are able to response to increased FGF23 concentration within 15 minutes by acti-
vating a FGFR1-calcineurin dependent pathway which downregulates serum PTH levels
[97]. PTH-KL−/− mice with adenine induced CKD were not able to decrease serum PTH
levels in a calcineurin dependent manner similar to CKD mice and rats expressing Klotho
in the parathyroid gland [97]. The way FGF23 activates FGFR1 receptors in the absence
of Klotho is not yet known.
1.4.4 FGF23 processing
FGF23 inactivation by SPC cleavage
In FGF23 transfected COS-7 cells, endogenous furin type convertase, a member of the
subtilisin-like proprotein convertase (SPC) family, is responsible for FGF23 cleavage at the
SPC cleavage site motive RXXR at position 176RHTR179 (see Figure 1.4) [65, 98]. Furin
inhibitors block FGF23 hydrolysis in a dose dependent manner [65]. Autosomal dominant
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hypophosphatemic rickets (ADHR) is caused by missense mutations in FGF23 gene [98].
Patients carrying an ADHR mutation suffer from hypophosphatemia and consequently
from osteomalcia or rickets [99]. In ADHR mutations, the arginine (R) residues within
the SPC cleavage site RXXR motive are missing [98]. Transfection of different cell lines
with either wildtype or ADHR mutated FGF23 showed that changes in the RXXR mo-
tive makes FGF23 less sensitive to proteolytic cleavage [64, 65, 100]. Hence, conditioned
media of wild type transfected cells contained beside full-length FGF23 also FGF23 frag-
ments whereas conditioned media of ADHR mutated FGF23 contained only the full-length
FGF23 [64, 65, 100]. In mice, administration of full-length FGF23 protein but not C- or
N-term fragments leads to renal phosphate wasting which means that proteolytic cleavage
inactivates FGF23 [64]. Further ADHR mutations change the O-glycosylation pattern of
FGF23 [64] but have no effect on the secretion of FGF23 into the cell supernatant and
the interaction of FGF23 with heparin [100].
Mucin-type O glycosylation of FGF23
FGF23 has four possible O-glycosylation sites localized either around the SPC cleavage site
at position 162-175 (1 site) as well as at position 176-178 (2 sites) or in a more C-terminal
fragment (199-228, 1 site) [64]. Mucin-type O-glycosylation is initiated by enzymes of
the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc transferases)
family which add N-acetylgalactosamine (GalNAc) to serine or threonine residues [101].
FGF23 O-glycosylation at position T171 can be performed by different isoforms of GalNAc
transferases whereas the O-glycosylation of T178 within the SPC cleavage site is only initi-
ated by the GalNAc-T3 isoform [102]. In vitro studies have shown that O-glycosylation by
GalNAc-T3 at T178 following sialylation of the sugar prevents FGF23 from SPC cleavage
[102]. Mutations in the GALNT3 gene causes familial tumoral calcinosis which mani-
fests itself by hyperphosphatemia and ectopic calcifications [103–105]. The lack of O-
glycosylation at T178 of FGF23 leads to the immediate degradation of the protein already
within the cell [102]. Hence, patients affected by mutations in the GALNT3 gene have
highly elevated plasma levels of C-term FGF23 whereas levels of intact FGF23 are very low
[105, 106]. The amount of intact FGF23 is not sufficient to induce appropriate phospha-
turia in the kidney and is the reason for hyperphosphatemia in these patients [105, 106].
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Due to reduced FGF23 signaling, patients tend to have higher 1,25 (OH)2 vitamin D3 lev-
els which promote hyperphosphatemia by increased Pi uptake in the intestine [105, 106].
In the Galnt3 KO mouse model it has been shown that FGF23 gene expression in bone is
14-fold increased but due to the fast degradation, FGF23 plasma levels are half of that of
wild type mice [107]. Interestingly, Klotho gene expression in kidneys of Galnt3 KO mice
is also elevated which suggests that Klotho itself is regulated by serum Pi or FGF23 levels
[107]. O-glycosylation of FGF23 by GalNAc-T3 is a critical step in the course of FGF23
processing by preventing premature inactivation of the protein by SPCs.
Phosphorylation of FGF23
Fam20C is a secreted as well as golgi-localized protein kinase which recognizes SXE (serine-
X-glutamic acid) motives [108, 109]. This motive is found in several secreted proteins,
among them the group of small integrin-binding ligand, N-linked glycoproteins (SIBLING)
[108]. The following five highly phosphorylated proteins belong to the SIBLING family:
osteopontin (OPN), dentin matrix protein 1 (DMP-1), bone sialoprotein (BSP), matrix ex-
tracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein [108]. Fam20C
phosphorylates SIBLING proteins in vitro in a time dependent manner whereas inactivat-
ing mutations of Fam20C are failing to do so [108, 109]. In humans, mutations in Fam20C
lead to the autosomal recessive Raine syndrome which results most often in death after
birth [110, 111]. Genetic defects in the FAM20C gene are causing osteosclerotic bone dys-
plasia including an increase of bone density in all bones, most prominent in the skull [110].
It could be shown that most of the FAM20C mutations are affecting either the secretion
or the kinase activity of the protein [108, 109]. Therefore decreased phosphorylation of
SIBLING proteins by FAM20C may contribute to the bone dysplasia phenotype of Raine
syndrome patients [108, 109]. Patients affected by non-lethal FAM20C mutations as well
as tissue specific conditional Fam20C KO animals display hypophosphatemia as well as el-
evated FGF23 expression levels [112, 113]. An in vitro study demonstrated that FAM20C
phosphorylates FGF23 S180 and thereby inhibits O-glycosylation of FGF23 by GALNT3
[114]. These results suggest that the regulation of FGF23 processing is a dynamic inter-
play between phosphorylation and O-glycosylation of FGF23. O-glycosylation increases
the secretion of the active form of FGF23 whereas phosphorylation promotes the cleavage
15
of FGF23 by furin and therefore the secretion of inactive N- and C-terminal FGF23 frag-
ments [114]. This interplay is disturbed in indivdiuals with viable FAM20C mutations
as well as in Fam20C KO animals and therefore intact serum FGF23 concentrations are
increased [114].
1.4.5 Regulation of FGF23 expression in bone
Local regulation of FGF23 expression in bone by Phex and Dmp-1
The phosphate-regulating gene with homologies to endopeptidases on the X chromosome
(Phex) shares high homologies with the membrane-bound metalloendopetpidase family
and is mainly expressed in bone [115]. Mutations in PHEX causes X-linked hypophos-
phatemia (XLH) which is characterized by rickets and hypophosphatemia due to impaired
phosphate reabsorption in the kidney [115]. The Hyp mouse is the homologous animal
model for XLH and suffers similar to humans from hypophosphatemia, impaired bone
mineralization, high serum PTH, and FGF23 as well as low 1,25(OH)2 vitamin D3 levels
[79, 115–117]. Mutations in Phex selectively increase FGF23 gene expression in bone and
cause therefore the phosphate wasting phenotype observed in Hyp mice [117]. Despite the
presence of hyerphosphatemia in Hyp/FGF23−/− double KO mice, the mineralization of
long bones is impaired which suggest that Phex has additional functions which are not
linked to FGF23 expression [117].
Dmp-1 belongs to the SIBLING protein family and is mainly expressed in mineralized
tissues and to a lower extent in nonmineralized tissues such as kidney, pancreas and brain
[118, 119]. Dmp-1 is secreted to the extracellular matrix where it is processed by Bmp-1
into a C-terminal 57kDa and a N-terminal 37kDa fragment [120, 121]. Mutations in DMP-
1 lead to autosomal dominant hypophosphatemic rickets (ADHR) [118]. ADHR manifests
itself as rickets and progressive lower limb deformity as well as hypophosphatemia, high
serum FGF23, and normal PTH and 1,25(OH)2 vitamin D3 levels [118]. Dmp-1 KO mice
display a similar phenotype to human ADHR and suffer from severe hypophosphatemia
due to increased renal phosphate clearance and increased serum PTH and FGF23 levels
whereas 1,25(OH)2 vitamin D3 levels are normal [118]. The increased serum FGF23 levels
are accompanied by increased FGF23 gene expression in bone and more specifically in
osteocytes which is also the main place of DMP-1 production [118, 122]. The upregulation
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of osteoblastic markers such as alkaline phosphatase and collagen type 1 expression as
well as the disorganization of osteocyte lacunae and the reduced bone mineralization in
Dmp-1 KO mice demonstrates that Dmp-1 deposition in the extracellular matrix is im-
portant for normal ostoblast-to-osteocyte differentiation as well as matrix mineralization
[118]. Double Phex/Dmp-1 KO mice have non additive effects regarding FGF23 gene and
protein expression and share their biochemical profile as well as the bone phenotype [123].
The phenotypic similarity of Hyp and Dmp-1 KO mice suggests that they regulate FGF23
expression through a common pathway [123]. Indeed pathway analysis of gene arrays of
Hyp, Dmp-1 and Hyp/Dmp-1 KO mice reveals activated FGFR1 signaling pathways in
all three mouse models [123]. Inhibition of FGFR1 in differentiated wild type mouse bone
marrow stromal cells reduces FGF23 expression as well as FGF23 promoter activity [123].
The involvement of FGFR1 in the regulation of FGF23 expression is also shown in the
short term treatment of Hyp mice with a selective, pan-specific FGFR inhibitor which
reduces FGF23 gene and protein expression in bone [124]. Overexpression of full length
or C-term Dmp-1 in Dmp-1 KO animals strongly decreases FGF23 expression and rescues
the Dmp-1 KO phenotype which indicates that the essential functional domains of Dmp-1
are within the C-terminal fragment [125]. To the contrary, overexpression of C-term Dmp-
1 in Hyp mice significantly impairs bone mineralization and doubles serum FGF23 levels
despite a 40% reduction in FGF23 gene expression [125]. Measuring the ratio between full
length and C-term FGF23 serum levels reveals that Hyp mice have proportionally higher
intact FGF23 than wild type mice and this ratio is even more increased in Hyp mice over-
expressing C-term Dmp-1 [125]. The increased ratio explains the FGF23 accumulation in
serum despite the reduced mRNA expression and attributes an important role to Phex
and Dmp-1 in the degradation process of the FGF23 protein [125]. The function of C-term
Dmp-1 is Phex dependent and the two proteins coordinate FGF23 production and bone
mineralization [125]. A hypothetical model could be that C-term Dmp-1 binds with its
acidic serine- and aspartate-rich motif (ASARM) to Phex and this interaction inhibits
FGF23 expression (Figure 1.6) [125]. The N-terminal Dmp-1 fragment binds to matrix
metalloproteinase 9 (MMP-9) and influences FGF23 protein degradation [125, 126].
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Figure 1.6: Regulation of FGF23 expression by Dmp-1 and Phex in mice. The C-term
Dmp-1 fragment binds to the ASARM sequence of Phex and thereby inhibits FGF23 expression
while the N-term Dmp-1 fragment binds to MMP-9 which increases the degradation of FGF23.
Adapted from Martin et al. (2012) [125].
Systemic regulation of FGF23 expression in bone
Many systemic factors were described to affect FGF23 expression in bone, among them
1,25(OH)2 vitamin D3, PTH, iron as well as soluble Klotho [127]. 1,25(OH)2 vitamin D3
is by far the best investigated factor which upregulates Fgf23 gene expression in bone.
Administration of 1,25(OH)2 vitamin D3 in mice leads to elevation of Fgf23 and reduction
of PTH serum concentration and is accompanied by an increase in Fgf23 gene expression
exclusively in bone [63, 77, 128]. The 1,25(OH)2 vitamin D3-induced change in Fgf23 ex-
pression is independent of changes in PTH levels [63]. Gcm2 KO animals have low serum
PTH and 1,25(OH)2 vitamin D3 levels due to an abnormal development of the parathy-
roid gland [63]. Administration of 1,25(OH)2 vitamin D3 to Gcm2 KO mice also increases
FGF23 expression [63]. In the Hyp mouse model, 1,25(OH)2 vitamin D3 is able to double
the already increased Fgf23 levels [63]. In rat osteosarcoma cell lines such as UMR-106
and Ros 17/2.8 cells, 1,25(OH)2 vitamin D3 leads to a dose and time dependent increase
in Fgf23 mRNA transcripts with a maximum peak after 24 hours [63, 128]. A promoter
activity assay performed in Ros17/2.8 rat osteosarcoma cells revealed that 1,25(OH)2 vi-
tamin D3 is a potent stimulator of Fgf23 promoter activity whereas Pi and calcium failed
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to do so [63]. Promoter mutants indicate that the vitamin D responsive region at FGF23
promoter position -1240 to -1161 is necessary for the activation of 1,25(OH)2 vitamin
D3-induced Fgf23 transcription [63]. Vitamin D receptor (VDR) is essential for increased
Fgf23 promoter activity following 1,25(OH)2 vitamin D3 stimulation. Ros17/2.8 cells over-
expressing VDR mutants do not have the same potency to induce 1,25(OH)2 vitamin D3
dependent FGF23 promoter activity compared to wild type cells [63].
PC2 mice suffer from primary hyperparathyroidism and have highly elevated serum cal-
cium, PTH, and Fgf23 levels whereas serum phosphate levels are decreased [129]. After
parathyroidectomy of PC2 mice, calcium, phosphate PTH and Fgf23 serum concentrations
return to a normal level [129]. This observation suggests that PTH stimulates FGF23 se-
cretion and therefore coordinates the lowering of serum calcium and phosphate levels under
hypercalcemic conditions to prevent ectopic calcification [129]. A similar observation was
made in parathyroidectomized wild type and CKD rats which showed reduced circulating
FGF23 and calcium levels as well as increased phosphate levels compared to sham operated
rats [130, 131]. The administration of physiological PTH doses to parathyroidectomized
rats normalized Fgf23 levels whereas the administration of supraphysiological PTH doses
led to strongly elevated Fgf23 levels [130]. Parathyroidectomized mice and rats show the
importance of PTH for Fgf23 secretion but unfortunately do not explain the molecular
mechanism of how PTH increases FGF23 levels. Ex vivo stimulation of calvarias from
wild type and uremic rats with PTH had no effect on Fgf23 gene and protein expression
whereas 1,25(OH)2 vitamin D3 did increase Fgf23 levels [132]. To the contrary, PTH in-
creases Fgf23 mRNA expression in UMR-106 rat osteosarcoma cells [131, 133]. Thereby
PTH activates protein kinase A (PKA) and induces expression of the nuclear receptor
related 1 protein (Nurr1) expression, a nuclear orphan receptor, also known as nuclear
receptor subfamily 4 group A member 2 (NR4A2) which leads to the subsequent increase
in Fgf23 gene expression [133–135]. Transient Nurr1 overexpression in UMR-106 cells
showed that Nurr1 in the absence of PTH is able to increase FGF23 promoter activity
and induces Fgf23 gene expression [133]. In addition, downregulation of Nurr1 by shRNA
prevents the PTH induced FGF23 expression in UMR-106 cells [133]. Within the FGF23
promoter Nurr1 binds to the NBRE binding element and activates FGF23 expression [133].
This supposes that PTH activates PTH receptors in osyteocytes which increases cAMP
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and PKA which leads to an increase in Nurr1 expression which then again is responsible
for an increase in Fgf23 gene expression [133]. An alternative intracellular pathway for
PTH dependent Fgf23 expression was reported by Lavi-Moshayoff et al. (2010). In this
model PTH is supposed to decrease Sost gene expression which is followed by a reduced
sclerostin protein production (product of Sost gene) [131]. Reduction in sclerostin leads to
the activation of the Wnt signaling pathway and releases β-catenin which increases Fgf23
expression [131].
Iron deficiency causes an increase of Fgf23 mRNA and protein levels in wild type as well as
ADHR mice [136]. To keep serum Pi levels in a normal range wild type mice compensate
the increased Fgf23 expression by increased proteolytic cleavage and consequently inac-
tivation of Fgf23 [136]. In ADHR mice, the increased FGF23 protein stability does not
allow Fgf23 inactivation and therefore results in Fgf23 induced hypophosphatemia [136].
UMR-106 rat osteosarcoma cells treated for 48 hours with the iron chelator deferoxamine
increase Fgf23 gene expression in a dose dependent manner [136]. The increase in FGF23
transcripts in response to low iron is dependent on MAP kinase and Hif1α and therefore
can be blocked by a MAP kinase inhibitor or stabilized by a Hif1α activator [136]. Ane-
mia in Gambian children is a frequent feature and goes along with increased FGF23 and
1,25(OH)2 vitamin D3 levels whereas serum PTH and phosphate levels were normal [137].
In these children hemoglobin levels are inversely correlated with serum FGF23 levels [137].
Iron deficiency is the primary cause for anemia in Gambian children throughout the year
for what reason Braithwaite et al. (2012) postulate that on one hand the low hemoglobin
level represents the poor iron status of these children and on the other hand low iron
levels could be an additional reason for elevated FGF23 beside the chronically low calcium
intake in this population group [137]. Women with iron deficiency anemia due to heavy
uterine bleeding have strongly elevated c-term FGF23 levels [138]. Administration of a
single dose iron dextran or ferric carboxymaltose increases not only hemoglobin and iron
indices but also lowers c-term FGF23 levels [138]. Further evidence that iron influences
FGF23 gene and protein expression was produced by the fact that iron deficiency in wild
type and ADHR female breeders during pregnancy and breastfeeding leads to increased
Fgf23 expression in their pubs [139]. Additional to iron deficiency hypoxia can upregulate
Fgf23 gene expression in UMR-106 rat osteosarcoma cells [139]. The exact link between
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iron deficiency and transcriptional regulation of FGF23 is not yet completely understood
and needs further evaluation.
The impact of circulating Klotho on Fgf23 expression in bone is not well explored. Never-
theless, a de novo translocation between chromosome 9 and 13 led in the affected patient
to inappropriate high circulating Klotho levels [140]. The patient suffered from 1,25(OH)2
vitamin D3 treatment independent increased FGF23 levels, elevated PTH levels, and hy-
pophosphatemia [140]. This observation triggered the hypothesis that circulating Klotho
directly regulates FGF23 expression in bone [140, 141]. Wild type mice treated with an
adeno-associated virus producing circulating Klotho which was driven by a liver specific
thyroxine-binding globulin promoter exhibit low serum phosphate and calcium levels due
to the circulating Klotho dependent upregulation of Fgf23 mRNA and protein expression
in bone [141]. The activity of the circulating Klotho was tested in NIH3T3 mouse fibrob-
last cells where it was able to activate only in presence of Fgf23 FGFR signaling [141].
Whether activated FGFR-Klotho-Fgf23 signaling in bone is responsible for elevated Fgf23
expression or whether there is an other circulating Klotho specific receptor is unclear and
needs further investigations.
1.5 FGF23 and inflammation
In recent years several studies have shown an association between inflammation and
FGF23. In the Chronic Renal Insufficiency Cohort (CRIC) the inflammatory marker
IL-6 and tumor necrosis factor alpha (TNFα) are increasing with ascending FGF23 quar-
tiles and significantly correlate with FGF23 levels independently of renal function and
measures of mineral metabolism [142]. Among the study participants with severe inflam-
mation FGF23 was a strong and independent risk factor for severe inflammation, but PTH
or Pi were not [142]. In the Reasons for Geographic and Racial Differences in Stroke Study
(REGARDS) ascending FGF23 quartiles in non CKD patients were as well associated with
markers of inflammation such as IL-6 and IL-10 [143]. Interestingly, FGF23 gene expres-
sion is increased in chondrocytes from patients with osteoarthritis, a disease characterized
by inflammation [144]. Additionally, children affected by inflammatory bowel disease
(IBD) have elevated circulating FGF23 protein levels that decrease in the remission phase
[145]. In a small IBD patient population, the treatment with infliximab, an anti-TNFα
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antibody, normalized FGF23 levels [145]. Trinitrobenzene sulfonic acid (TNBS) induced
colitis in mice is accompanied by an upregulation of Tnfα expression in colon and leads to
a decrease of Phex expression in bone [146]. The downregulation of Phex gene expression
is Tnfα dependent and can be reversed by the administration of an anti-Tnfα antibody
[146]. Further, Phex promoter activity in transfected UMR-106 cells is reduced by Tnfα
in a time and dose dependent manner [146]. Phex is known to inhibit FGF23 expression
in bone and therefore a TNFα induced reduction of Phex expression could be responsible
for the elevated FGF23 levels observed in childern with IBD [145].
Inflammatory stimuli such as TNFα, IL-1β and lipopolysaccharide (LPS) increased FGF23
expression in ex vivo cultured human trabecular bone as well as in IDG-SW3 cells, a mouse
osteocyte cell line [147]. Similar as in mice with IBD, Tnfα stimulation of IDG-SW3 cells
resulted in the downregulation of Phex gene expression [147]. Additionally, Tnfα increases
Galnt3 expression, the gene which encodes the protein responsible for O-glycosylation of
FGF23 [147]. Further evidence that FGF23 is involved in inflammation originates from
microarray data of the Col4a3−/−, Hyp and FGF23Tg mice, three models of FGF23 excess
[148]. In the kidneys of these three animal strains 31 genes were detected to be regulated
in at least two out of the three models of FGF23 excess [148]. An Ingenuity Pathway
Analysis performed with these 31 genes suggests an important role of the activation of
transforming growth factor beta (Tgfβ), Tnfα, nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1 (NFκB), IL-1β, interferon, and platelet derived growth factor
(PDGF) which is consistent with activation of inflammatory processes [148]. Intraperi-
tonal injection of LPS, E. coli or S. aureus in mice leads to an elevation of FGF23 serum
concentration [149]. In these mice, thymus, spleen, bone marrow, liver, and kidney but
not bone were evaluated as source of FGF23, out of them spleen was the only organ with
elevated FGF23 expression levels [149]. Within the spleen bone marrow derived dendritic
cells (BMDC) and to a lower extent macrophages were able to express FGF23 in response
to LPS, but lymphocytes were not [149]. In BMDC FGF23 expression was prevented by
a NfκB inhibitor [149]. There is growing evidence that FGF23 is involved in inflammatory
processes but further studies are needed to define the physiological role of FGF23 within
the inflammatory response.
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1.6 Chronic kidney disease (CKD)
CKD is a collective term for heterogeneous disorders affecting kidney structure and func-
tion over a period of more than 3 months [150]. The presence of CKD is bound to a drop
in GFR (see Table 1.1), an increase in albuminuria (see Table 1.2) and the presence of
systemic diseases or pathological anatomic findings within the kidney [150]. CKD progres-
sion is promoted by risk factors such as hypertension, diabetes mellitus type 2, obesity,
inherited kidney diseases, and cardiovascular disease [151, 152]. Therefore, prevention of
these disease mediators by control of blood pressure, dietary intake of protein, salt, and
minerals as well as glycemic control are effective in slowing down disease progression and
delay end stage renal disease (ESRD) [150]. In an advanced CKD stage (GFR category
5), patients reach end stage renal disease (ESRD) and rely on renal replacement therapy
such as dialysis or kidney transplantation [150].
The prevalence of CKD worldwide is estimated to be 8-16% [152]. According to the Global
Burden of Disease study 2013, CKD ranks with an age-standardized annual death rate
of 15.8 per 100’000 (CI 13.5-17.1) at position 19 in the list of causes of total number of
global deaths [153]. Especially at the time when patients reach ESRD and when renal
replacement therapy is initiated, the mortality of CKD patients increases strongly [154].
The large number of CKD patients causes health care cost in a not negligible range. For
example, the US Medicare social health insurance spends annually about $44.6 billion for
health costs of CKD patients older than 65 years [151]. This number does not include
ESRD patients. This represents approximately 20% of the overall health cost covered by
the insurance in this age class [151]. Furthermore, ESRD patients of all ages cost Medi-
care $28.6 billion which corresponds to 5.6% of their total expenses [151]. To reduce costs
caused by CKD, it is important to raise the consciousness of people for CKD and prevent
the disease progression by medication and adequate lifestyle [150, 152]. Additionally, bet-
ter understanding of the disease itself and identification of risk factors responsible for the
high mortality rate of the CKD population is necessary to improve CKD outcome [155].
1.6.1 Disturbance of mineral homeostasis in CKD
The decrease of renal function in the course of CKD entails stepwise changes in mineral
homeostasis (see Figure 1.7) [156–158]. The gradual decrease of soluble Klotho in urine
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Table 1.1: GFR categories in CKD. Adapted from Levin et al. (2014) [150].
GFR GFR (ml/min Terms
category per 1.73m2)
G1 > 90 Normal or high
G2 60 - 89 Mildly decreased*
G3a 45 - 59 Mildly to moderately
G3b 30 - 44 Moderately to severely decreased
G4 15 - 29 Severely decreased
G5 < 15 Kidney failure
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
* Relative to young adult level
In the absence of evidence of kidney damage, neither GFR category G1 or G2
fulfill the criteria for CKD
Table 1.2: Albuminuria categories in CKD. Adapted from Levin et al. (2014) [150].
ACR (approximate
equivalent)
AER
Category (mg/24h) (mg/mmol) (mg/g) Terms
A1 < 30 < 3 < 30 Normal to mildly increased
A2 30 - 300 3 - 30 30 - 300 Moderately increased*
A3 > 300 > 30 > 300 Severely increased**
Abbreviations: ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; CKD,
chronic kidney disease.
*Relative to young adult level.
**Including nephrotic syndrome (albumin excretion usually >2200mg/24 h (ACR
> 2220 mg/g; > 220mg/mmol)).
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and serum from CKD patients starting at CKD stage G1 belongs to the first events hap-
pening in the sequence of changes in mineral homeostasis [46, 158, 159]. Subsequently,
FGF23 significantly raises at an eGFR threshold of 57.8 ml/min per 1.73 m2 [157]. The
Col4a3−/− KO mouse, a CKD animal model, displays as well an early increase in FGF23
in the course of CKD [160]. Interestingly, FGF23 gene expression in bone of these an-
imals is unchanged at early CKD stages and increases just at the time when the mice
are reaching ESRD [160]. Thus, it is unclear whether the early rise in FGF23 is due to
enhanced stability of FGF23 protein because of posttranslational modification or due to
the expression of FGF23 in other organs than bone [160]. The elevated FGF23 is thought
to suppress 1,25(OH)2 vitamin D3 synthesis and initiate the pathogenesis of secondary
hyperparathyroidism [156, 157]. The dependence of low 1,25(OH)2 vitamin D3 levels in
CKD on FGF23 levels is demonstrated in a CKD rat model where a single injection of
anti-FGF23 antibody is able to normalize 1,25(OH)2 vitamin D3 levels [161]. The low
1,25(OH)2 vitamin D3 levels further contribute to the reduction of Klotho expression
[162, 163]. The GFR threshold for PTH lies at 46.9 ml/min per 1.73 m2 and occurs later
in the course of CKD compared to the rise in FGF23 [157]. This is also illustrated by the
fact that in CKD stage G2 to G3a the most common pattern is high FGF23 (FGF23 ≥
100RU/ml) combined with normal PTH levels (PTH < 65 pg/ml) whereas in CKD stage
G3b to G4 the predominant pattern is high FGF23 (FGF23 ≥ 100RU/ml) combined with
high PTH levels (PTH ≥ 65 pg/ml) [157]. Therefore, the rises in FGF23 levels precedes
the increase of PTH in CKD [157]. Hyperphosphatemia occurs even later in the course of
CKD [156, 157]. Serum phosphate is decreasing in an initial phase (eGFR > 59.1ml/min
per 1.73 m2) which goes along with the increase in FGF23 and the fractional excretion
of phosphate as well as the decrease in 1,25(OH)2 vitamin D3 [157]. In the second phase,
there is a shift where serum phosphate levels gradually increase with eGFR < 59.1ml/min
per 1.73 m2 [157]. Hyperphosphatemia is present only in advanced CKD stages [156, 157].
The ”Trade-off hypothesis” according to Bricker et al. (1972) suggests that reduced eGFR
in CKD represents a reduction in nephron mass and therefore the total remaining nephrons
have a reduced phosphate clearance [164]. To maintain phosphate clearance in spite of the
reduced eGFR, the remaining nephrons have to excrete more phosphate per unit [164].
The implementation of the ”Trade-off hypothesis” into the changes in mineral homeostasis
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in CKD suggests that Klotho deficiency demands an increased phosphate clearance per
nephron which is achieved by elevation of FGF23 levels [165]. This adaptation involves
the trade-off of continuous decreasing 1,25(OH)2 vitamin D3 levels and the consequential
development of secondary hyperparathyroidism [165]. Recently it has been shown that
FGF23 levels, similar to phosphate levels, are highly associated with the relative risk of
death in ESRD patients undergoing hemodialysis [155, 166]. This association between
FGF23 and mortality is independent of serum phosphate levels and considerably stronger
compared to the association between mortality and serum phosphate levels [166]. Hence,
FGF23 excess in CKD is important for the maintenance of phosphate balance in reaction
to reduced phosphate clearance but at the same time FGF23 excess is responsible for the
development of secondary hyperparathyroidism as well as linked to the increased mortality
in ESRD patients [165].
The reduction of FGF23 levels in early CKD is important to normalize vitamin D3 levels,
prevent secondary hyperparathyroidism, and reduce mortality. The achievement of this
goal with simultaneous control of serum phosphate levels is challenging and so far not
possible. Efforts to block FGF23 action in the kidney have not been completely successful
in selectively blocking its effect on vitamin D3 synthesis but preserving its phosphaturic
action which is beneficial in preventing hyperphosphatemia. The administration of anti-
FGF23 antibodies in rodents suffering from CKD normalizes 1,25(OH)2 vitamin D3 levels
and prevents secondary hyperparathyroidism but on the other hand it leads to hyper-
phosphatemia [161, 167]. Hyperphosphatemia causes vascular calcification and increases
mortality in CKD rats [167]. Other strategies to target FGF23 include inhibiting the sig-
naling cascade at various levels in the kidney. This was done primarily in the Hyp mouse, a
model of FGF23 excess due to mutation in the Phex gene [65, 115]. Because of constitutive
activated ERK1/2 signaling caused by FGF23 excess, these rodents suffer from hypophos-
phatemia, impaired bone mineralisation and vitamin D3 deficiency [89, 90, 116, 168, 169].
Long term blocking of FGFR receptors with a panspecific FGFR inhibitor in Hyp mice cor-
rects hypophosphatemia and leads to enhanced bone mineralization [124]. Short and long
term inhibition of ERK1/2 signaling in Hyp mice reduces expression of the transcription
factor Egr-1 and normalizes 1,25(OH)2 vitamin D3 levels [89, 90]. Furthermore, the treat-
ment partially corrects hypophosphatemia by upregulating NaPi-IIa protein abundance
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at the brush border membrane [89, 90] and improves bone mineralization [90]. Addition-
ally, the ERK1/2 blockade in Hyp mice leads to an increase in FGF23 gene expression in
bone and to an increase in circulating FGF23 levels [90]. The effect of increased FGF23
expression in bone on the mortality of the Hyp mouse was not evaluated. Hyp mice lack-
ing one allele of FGF23 have a 40% reduction in FGF23 plasma levels compared to Hyp
mice [117]. Similar to ERK1/2 blockade, 1,25(OH)2 vitamin D3 levels are corrected in
Hyp/FGF23+/− mice whereas hypophosphatemia remains [117]. Therefore, the effect of
FGF23 on renal 1,25(OH)2 vitamin D3 production and renal phosphate reabsorption un-
derlies different regulations [90]. These studies show that the intervention in phosphate
homeostasis in CKD is extremely delicate and the system of adaption and maladaption
in CKD is complex [170]. Hence, FGF23 regulation and its action in CKD as well as the
mechanism how mortality is influenced by FGF23 has to be elucidated to modulate and
influence CKD outcome in the future.
Figure 1.7: Disregulation of mineral homeostasis in CKD. Proposed time profile of changes
in Klotho, serum phosphate levels and hormones relevant to mineral metabolism in CKD. The x-
axis represents the decline in renal function from stage 1 to 5 of CKD based on eGFR. Adapted
from Hu et al. (2013) [46].
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1.7 Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenetic disorder and
occurs worldwide with a prevalence of 1 to 1000 [171]. ADPKD is caused by mutations
in the PKD1 (85%) or PKD2 (15%) genes which encode the polycystin 1 (PC1) and
polycystin 2 (PC2) protein, respectively [172–177]. Patients affected by ADPKD suffer
from bilateral kidney enlargement where functional renal tissue is progressively replaced
by growing cysts [177]. Although the size of cysts within and between the kidneys is
highly variable, the kidney enlargement proceeds at a steady rate specific for each patient
[177]. ADPKD is a cause for CKD and the progression of the disease leads to ESRD
[151]. In the US, ADPKD patients represent approximatly 6% of the ESRD population
[151]. In ADPKD, smaller kidney volumes are related to lower changes in GFR whereas
in larger kidneys the decline in GFR is accelerated [177]. This means that ADPKD pa-
tients compensate the loss of renal units resulting from cyst growth with hyperfiltration,
thereby keeping GFR over a long period of time constant [178]. Therefore eGFR is not
an accurate predictor for disease progression in early ADPKD [177, 178]. Hypertension is
an accompanying symptom of ADPKD which occurs before the decline in GFR [179–181].
Hypertension in ADPKD is associated with the magnitude of renal structural abnormal-
ities for this reason hypertensive ADPKD patients have a larger kidney volume than
non-hypertensive ADPKD patients [180]. In this context, hypertension is most probably
due to the compression of renal vasculature by growing cysts which causes bilateral renal
ischemia and activates the renin-angiotensin-aldosterone system [179, 180, 182]. Another
feature of ADPKD are liver cysts which are particularly prevalent in older ADPKD pa-
tients and more frequent in patients with large kidney volumes [183]. Women and in
particular women who underwent pregnancy are more affected by liver cysts than men
[183].
ADPKD patients with a preserved renal function and CKD stage 1 or 2 have 4-fold in-
creased FGF23 levels compared with non-diabetic patients or patients with diabetes mel-
litus type 2 and a similar CKD stage, whereas PTH and 1,25(OH)2 vitamin D3 levels still
remain in the normal range [184]. The elevated FGF23 is functionally active as demon-
strated by a positive correlation between serum phosphate levels and tubular maximal
phosphate reabsorption per eGFR [184]. The early rise in FGF23 is a specific manifes-
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tation in ADPKD and cannot be explained by the loss of renal function as discussed in
section 1.6.1 because in this patient population the eGFR is still preserved [184]. Inter-
estingly, only ADPKD patients with normal soluble Klotho levels show a mild decrease in
plasma phosphate levels whereas the majority of ADPKD patients have low serum Klotho
levels [184, 185]. Klotho is the obligate co-receptor for FGF23 signaling and its absence
can account for the FGF23 resistance observed in ADPKD patients [184, 185].
The course of ADPKD is extremely heterogeneous and largely depends on the type of
mutation and on the gender [186–188]. Patients carrying a mutation in PKD1 gene reach
death or ESRD at a median age of 53-58.1 whereas patients with mutations in PKD2
gene have a median age of 69.1-79.7 at ESRD [186–188]. A similar trend is observed for
the diagnosis of hypertension which is made in PKD1 mutation carriers at a mean age of
38.6 and in PKD2 mutation carriers at a mean age of 48.6 [186]. Furthermore, truncating
PKD1 mutations such as frameshift, nonsense, or splice mutations and large rearrange-
ments are leading to an earlier onset of ESRD (median age 55.6) than non-truncating
mutations such as in-frame and missense mutations (age 67.9) [186].
Genetic testing and imaging methods allow ADPKD diagnosis before a detectable decline
in renal function occurs, thus ADPKD is a useful model to study the whole process of
CKD development [189].
1.7.1 Function of PC1 and PC2
Although the genes related to ADPKD have been known for two decades the exact func-
tion of PC1 and PC2 is not completely understood. PC1 is a large glycosylated protein
with a long extracellular N-terminal region (2550 amino acids), an eleven transmembrane
domain (1500 amino acids), and a short C-terminus (225 amino acids) [175]. Within the
extracellular part of the protein multiple domains such as leucine reach repeats, a C type
lectin domain, immunoglobulin-like repeat, and type III fibronectin related domains were
identified [175]. These structures are important for the interaction with other cells and the
extracellular matrix as well as with signaling molecules [175]. The intracellular domain
contains several phosphorylation sites for tyrosine kinases and PKC [175]. PC2 consists
of 968 amino acids and is an integral membrane protein with 6 transmembrane regions
and an intracellular N- and C-terminus [176]. PC2 is a nonselective cation channel with a
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high permeability to Ca2+ and it shows high sequence similarity with transient receptor
potential channels and voltage gated Ca2+ channels [190–192].
PC1 and PC2 are co-localized at the primary cilia, cell-cell or cell-matrix adhesion sites
[193, 194]. The C-terminal cytoplasmic tails of PC1 and PC2 interact with each other at
a coil-coiled domain and form a heterodimeric complex [195]. This polycystin complex en-
ables PC2 to function as an ion channel [192, 195]. Additionally, PC2 proteins are able to
form homodimers by binding to a specific C-terminal cytoplasmic region which is different
from the PC1-PC2 interaction site [195]. Mutations in the C-terminal domain of PC1 and
PC2 reduce the binding affinity of the two proteins to each other and therefore, by caus-
ing miss-localization or inadequate pore formation, prevent the formation of a functional
channel [192]. In the primary cilia, PC1 and PC2 transduce external mechanical flow
stimuli into a intracellular calcium signal [196]. Thereby the large extracellular domain
of PC1 acts as a mechano-fluid stress sensor and senses the bending of the primary cilia
in response to fluid flow [196]. The subsequent activation of the PC2 Ca2+ channel by
PC1 transforms the mechanical signal into a chemical response and leads to a local Ca2+
influx into the primary cilium [196]. The change in the intracellular Ca2+ concentration
triggers intraorganellar Ca2+ release within the cytoplasm through Ca2+-induced Ca2+
release [196]. In vitro experiments showed that renal cells lacking PC1 are not able to
respond to fluid flow and lose their ability to act as a mechanosensory organelle [197].
The study of Pkd1 KO models showed that PC1-PC2 signaling is important in kidney
as well as pancreas, cardiovascular, cartilage, and bone development [198–200]. Homozy-
gous Pkd1 KO mice show normal histological development until day E14.5 but thereafter
progressive tubule dilatation and subsequent cyst formation lead most of the animals to
die at an embryonic stage [198–200]. In the developing kidney, PC1 expression increases
strongly from E15.5 to E18.5 and can be localized to mesenchymal cells and endothelial
cells in the nephrogenic zone as well as the differentiating tubules of the nephron and the
collecting duct system [200]. This matches the time and place where cyst development
occurs in Pkd1 KO animals and identifies PC1 as a critical protein influencing renal tubule
maturation [198–200]. Mutations which lead to a partially functional PC1 protein have a
reduced rate of cyst formation but the onset of cyst developing is comparable to Pkd1 null
mice [199]. This suggests that the type of mutation influences disease progression in mice
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like in humans as mentioned above [199]. Besides kidney phenotype, mice lacking Pkd1
display a markedly impaired skeletogenesis which finds expression in osteochondrodyspla-
sia and delayed endochondral and intramembranous bone formation [199, 200]. There is
no bone phenotype in human ADPKD patients which most likely is due to the fact that
homozygous individuals die in utero [199].
To bypass the early mortality in Pkd1 KO mice and the fact that heterozygous animals
rarely develop cysts before 6 months, conditional Pkd1 KO animals were generated by
the group of Gregory Germino [201]. In this mouse model PC1 exons 2-4 are flanked by
unidirectional loxP sites [201]. Mice homozygous for the floxed Pkd1 (Pkd1fl/fl) allele
are viable, fertile, and born at the expected Mendelian ratio [201]. In the presence of Cre
recombinase the floxed Pkd1 sequence is excised which leads to a complete null allele and
renal cyst formation [201]. Therefore the floxed Pkd1 mouse strain serves as a model to
investigate the effect of temporally and spatially inactivation of the Pkd1 gene [201]. For
example, the Pkd1fl/fl mouse in combination with a tamoxifen inducible Cre driven by
the beta-actin promoter allows a distinct temporally inactivation of Pkd1 in the whole
mouse whereas Pkd1fl/fl in combination with a kidney specific cadherin Cre leads to an
inactivation of Pkd1 specifically in parts of the kidney [202, 203]. The time point of Pkd1
inactivation defines the kinetics of kidney cyst formation, an induction till day 12 post
partum results in severe cystic disease within 3 weeks whereas an induction after day 14
results in a late onset cystic disease where cysts appear after 3 month and become severe
after 6 month [202, 203]. The slow PKD disease progression model is an ideal system to
study the sequential hormonal changes observed in CKD.
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Chapter 2
Hypothesis and aims
This project is based on the clinical observation that ADPKD patients have elevated
plasma FGF23 levels while their renal function is still normal [184]. The reason for this
abnormal regulation of FGF23 is so far unknown.
The aims of this study are:
1. Examine the role of high Fgf23 in PKD rodent models (Han:SPRD rats cy/+ and
Pkd1 conditional KO mice)
2. Investigate the regulation of Fgf23 expression in bone and the de novo Fgf23 expres-
sion in kidney cell culture
3. Test the hypothesis that local hypoxia or inflammation triggers ectopic Fgf23 ex-
pression
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3.1.1 Abstract
Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked to
cardiovascular disease and all-cause mortality in chronic kidney disease. FGF23 rises in
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patients with CKD stages 2-3 whereas in patients with autosomal dominant polycystic
kidney disease (ADPKD), the increase of FGF23 precedes the first measurable decline in
renal function. The mechanisms governing FGF23 production and effects in kidney disease
are largely unknown. We examined the correlation between FGF23 and its effects on min-
eral homeostasis in two PKD animal models. Plasma FGF23 levels were 10-fold increased
in 4 weeks old cy/+ Han:SPRD rats, whereas plasma urea and creatinine concentrations
were similar to controls. Plasma calcium and phosphate levels as well as TmP/GFR
were similar in PKD and control rats at all time points. Expression and activity of renal
phosphate transporters, the vitamin D3 metabolizing enzymes, and the FGF23 co-ligand
Klotho in the kidney were similar in PKD and control rats at 2, 4 and 8 weeks, indicating
resistance to FGF23. However, phosphorylation of the FRS2α protein was enhanced. In
PKD kidneys FGF23 mRNA was highly expressed and FGF23 protein was detected in
cells lining renal cysts. FGF23 expression in bone and spleen was similar in PKD and
healthy animals. Similarly, in an inducible Pkd1 knockout mouse model plasma FGF23
levels were elevated, FGF23 was expressed in kidneys whereas renal phosphate excretion
was normal. Thus, the polycystic kidney produces FGF23 but is resistant to it.
3.1.2 Introduction
Systemic phosphate homeostasis is regulated by a variety of factors including dietary
intake, intestinal absorption, skeletal turnover, renal excretion, and systemic acid-base
status as well as by many hormones. Among them parathyroid hormone (PTH), vitamin
D3, and fibroblast growth factor 23 (FGF23) act in concert at various levels of systemic
phosphate homeostasis [39, 40, 204–211].
FGF23 is a recently discovered member of the fibroblast growth factor family and is mainly
expressed in bone and to a lesser extent in spleen, and brain but not in kidney [59, 65].
The kidney is the major target regulating phosphate reabsorption as well as vitamin D3
metabolism [69, 77]. FGF23 acts on the distal convoluted tubule which may lead to the
triggering of a cascade that reduces proximal tubular phosphate reabsorption [212, 213].
Alternatively in the proximal tubule FGF23 activates ERK1/2 and SGK1 phosphoryla-
tion (SGK1) [83]. Phospho-SGK1 enables the phosphorylation of the sodium hydrogen
exchanger regulatory factor (NHERF1) thereby allowing the internalization of the sodium
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phosphate cotransporter NaPi-IIa from the brush border membrane [83]. Consequently
the reabsorption of phosphate from the glomerular filtrate will decrease [83, 212, 213].
Furthermore, FGF23 reduces the plasma concentration of 1,25(OH)2 vitamin D3 through
downregulation of Cyp27b1 (1α-hydroxylase) in the proximal tubule, the responsible en-
zyme for the 1α-hydroxylation of 25(OH) vitamin D3, and the upregulation of Cyp24a1
(24-OHase), the responsible enzyme for the degradation of active 1,25(OH)2 vitamin D3
[69, 77].
The severe disturbance of phosphate homeostasis accounts for morbidity and mortality in
patients with endstage renal disease [155]. FGF23 is elevated in patients with CKD stages
2 and 3 whereas PTH increases significantly later [156, 157, 214, 215]. In haemodialysis
patients FGF23 contributes to the excessive morbidity and mortality independently of
serum phosphate and PTH levels [155]. Moreover, CKD patients suffer from low vitamin
D3 which may be caused at least in part by high FGF23 levels [156–158]. Similarly, rats
with progressive kidney disease showed elevated FGF23 levels [161]. In these animals, a
neutralizing FGF23 antibody led to hyperphosphatemia and normalized 1,25(OH)2 vita-
min D3 levels [161].
ADPKD is a slowly progressive disease that is manifested by the replacement of functional
renal tissue with growing cysts [171]. The responsible mutations lie in the PKD1 and PKD2
genes, encoding the two transmembrane proteins polycystin-1 (PC1) and polycystin-2
(PC2), respectively [172–176]. ADPKD patients have 4-fold increased FGF23 levels even
before renal function declines [184]. Among these patients, only those with normal soluble
α-Klotho, showed a mild decrease in plasma phosphate values [184, 185].
The Han:SPRD rat is a well-established PKD animal model with a mutation in the Pkdr1
gene that encodes the SamCystein protein [216, 217]. The slow progression of cystic kid-
ney disease with a significant increase of creatinine and urea serum concentrations after 8
weeks is typical for heterozygous male animals (cy/+) [218]. Cysts in the cy/+ animals
originate mainly from the proximal tubule similar to mice with a deletion in the Pkd1
gene [218, 219]. The PKD model has been widely used for examining mechanisms and
therapies for ADPKD [220–223].
We investigated the regulation of renal phosphate handling, FGF23 expression, and pro-
duction in two PKD animal models. We found that the polycystic kidney produces FGF23
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but is resistant to it.
3.1.3 Results
Plasma concentrations of FGF23 and PTH
FGF23 plasma concentrations were increased in cy/+ Han:SPRD rats compared with wild
type (+/+) animals at all time points studied (Figure 3.1a). At week 2, the difference in
FGF23 concentration between cy/+ (55 ± 27pg/ml) and +/+ animals (35 ± 11 pg/ml)
was 20 pg/ml (95% CI 0.5 − 39 pg/ml). FGF23 plasma levels further increased in cy/+
animals to 549 pg/ml after 4 weeks (mean difference 497 pg/ml, 95% CI 444 − 549 pg/ml).
FGF23 concentration in cy/+ animals remained approximately 10-fold higher at 6 and 8
weeks compared with controls. PTH plasma concentrations were similar in cy/+ and
+/+ animals at 2 weeks (Figure 3.1b) whereas after 4 weeks, PTH levels of cy/+ animals
were 2-fold elevated (141 ± 16 pg/ml) compared with +/+ animals (63 ± 6 pg/ml) (mean
difference 78 pg/ml, 95 % CI 64− 92pg/ml). PTH concentration in cy/+ animals remained
2-fold higher at 6 and 8 weeks.
The renal function parameters plasma creatinine and urea were similar for cy/+ and +/+
animals from birth to week 4, thereafter the values were higher in cy/+ compared with +/+
animals (Figure 3.1c and d). The estimated change of plasma creatinine per week in cy/+
animals was 2 µmol/l (95 % CI 1 − 3 µmol/l) and 0.8 µmol/l (95 % CI 0.7 − 1 µmol/l) in
+/+ animals. For urea, the estimated change per week was 0.6 mmol/l (95% CI 0.4 − 0.9
mmol/l) in cy/+ animals and 0.1 mmol/l (95% CI 0.1 − 0.2 mmol/l) in +/+ animals. At
week 4, we measured plasma phosphate and calcium as well as TmP/GFR and creatinine
clearance of cy/+ and control Han:SPRD rats after an overnight fast (Supplementary
Figure 3.11). All parameters were similar in both groups.
FGF23 expression in cystic kidneys
In order to identify the source(s) of elevated FGF23 in cy/+ Han:SPRD rats, we extracted
mRNA from bone, kidney, spleen, heart, and liver and assessed FGF23 mRNA expression
by semi-quantitative real-time PCR. In bone, FGF23 expression increased over time in
cy/+ and healthy animals but there were no differences between the groups at all time
points studied (Figure 3.2a). In addition, we detected stable FGF23 mRNA expression
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Figure 3.1: FGF23, PTH and renal function. Plasma concentrations of FGF23 (a), PTH
(b), creatinine (c) and urea (d) after 2, 4, 6, and 8 weeks in cy/+ (black squares) and +/+ (white
squares) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 11.5, +/+ = 11; *
p<0.05 and ** p<0.001
in spleen whereas no FGF23 mRNA expression was found in liver and heart tissue in
both animal groups (results not shown). In polycystic kidneys increasing levels of FGF23
mRNA were detectable after 4 weeks. However, in healthy kidneys no FGF23 mRNA
expression was detected (Figure 3.2a). FGF23 protein expression was detected by im-
munohistochemistry in cells lining the cysts in kidneys from cy/+ Han:SPRD rats but
not in control kidneys (Figure 3.2b-f). Dmp1 and Fam20c modulate FGF23 expression
in bone. We detected mRNA of both molecules in rat kidney at high levels. Fam20c
expression was similar in cy/+ and control rats but Dmp1 expression was increased in
kidneys from 8 weeks old cy/+ rats (Supplementary Figure 3.12).
1,25(OH)2 vitamin D3 metabolism
Plasma 1,25(OH)2 vitamin D3 levels were similar among cy/+ and control animals at
2, 4, and 8 weeks (Figure 3.3a). In both groups 1,25(OH)2 vitamin D3 levels decreased
similarly over time. The relative mRNA expression of vitamin D receptor (VDR) is similar
in both groups whereas there is a reduction of VDR from week 4 to 8 in cy/+ animals
(Figure 3.3b). In addition, the relative mRNA expression of Cyp27b1 and Cyp24a1, the
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Figure 3.2: FGF23 expression in kidney. (a) Relative mRNA expression of FGF23 to 18S
rRNA in bone and kidney after 2, 4, and 8 weeks in cy/+ (black bars) and +/+ (white bars)
Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, +/+ = 5.5; ** p<0.001.
Immunohistochemistry for FGF23 (green), calbindin D28k (red), a marker for distal convoluted
tubules and connecting tubules, and DAPI (blue, cell nuclei): (b,c) kidneys from 8 week old cy/+
rats, (d,e) kidneys from 8 week old control rats, (f) kidney from 8 week old cy/+ rat incubated
with secondary antibodies alone. Original magnification 400 x.
major enzymes responsible for vitamin D3 metabolism was measured (Figures 3.3c and d).
The mRNA expression of the catabolic enzyme Cyp24a1 was higher at 2 weeks in cy/+
animals. However, the expression of Cyp24a1 was similar in cy/+ and +/+ animals after
4 and 8 weeks. For the anabolic enzyme Cyp27b1, we detected similar mRNA expression
levels in the cy/+ and +/+ groups at all time points studied.
Renal phosphate and calcium handling
To evaluate the biological effect of high FGF23 plasma levels, we measured phosphate and
calcium concentrations in blood and urine. The plasma phosphate and calcium levels as
well as the renal excretion of calcium and phosphate were similar among cy/+ and +/+
animals at all time points studied (Figure 3.4).
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Figure 3.3: Vitamin D3 metabolism. Plasma concentration of 1,25(OH)2 Vitamin D3 (a),
relative mRNA expression of the vitamin D receptor (VDR) (b) as well as Cyp27b1 (c) and Cyp24a1
(d) enzymes in the kidney to 18S rRNA after 2, 4, and 8 weeks in cy/+ (black bars) and +/+
(white bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, +/+ = 5; *
p<0.05 and ** p<0.001.
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Figure 3.4: Renal phosphate and calcium handling. Plasma concentrations of phosphate
(a) and calcium (b) as well as TmP/GFR (c) and FECa ratio (d) after 2, 4, 6, and 8 weeks in
cy/+ (black squares) and +/+ (white squares) Han:SPRD rats (mean ±SD); number of animals
(median), cy/+ = 11.5, +/+ =11; * p<0.05.
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Phosphate cotransporters NaPi-IIa and NaPi-IIc
The renal phosphate cotransporters NaPi-IIa and NaPi-IIc are downregulated by high
levels of FGF23. In our study, the mRNA and protein expression levels of NaPi-IIa and
NaPi-IIc were similar in both groups at 2, 4, and 8 weeks (Figures 3.5 and 3.6). Immunolo-
calization of NaPi-IIa protein in kidney sections of 4 and 8 weeks old cy/+ and +/+
animals demonstrated expression of NaPi-IIa protein in the brush border membrane of
proximal tubules and smaller cysts as evident from colocalization with actin (Supplemen-
tary Figure 3.13). At these time points, basolateral NaPi-IIa staining was absent, whereas
a prior report demonstrated aberrant NaPi-IIa localization in 32 weeks old Han:SPRD
rats [224].
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Figure 3.5: Phosphate transporter mRNA expression. Relative mRNA expression of NaPi-
IIa (a) and NaPi-IIc (b) to 18S rRNA after 2, 4, and 8 weeks in cy/+ (black bars) and +/+ (white
bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, +/+ = 6; * p<0.05.
Phosphate and glucose transport activities
We tested the sodium-dependent transport rate of 32-labeled phosphate into brush border
membrane vesicles in the absence and presence of phosphonoformic acid (PFA, 6 mM),
an inhibitor of NaPi-IIa and NaPi-IIc, and found similar transport rates among cy/+ and
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Figure 3.6: Phosphate transporter protein expression. Relative protein expression of NaPi-
IIa and NaPi-IIc to β-actin after 2 (a), 4 (b), and 8 (c) weeks in cy/+ (black bars) and +/+ (white
bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, +/+ = 6; * p<0.05.
control animals at 2 and 4 weeks (Figure 3.7). Na+-dependent phosphate uptake in the
absence of PFA was significantly increased in kidneys of 8 weeks old cy/+ rats. 3-H glucose
uptake was similar in both groups at all time points studied.
FGF23 and left ventricular hypertrophy (LVH)
High FGF23 plasma levels are associated with LVH [225]. We analyzed whether high
FGF23 levels in 4 and 8 weeks old rats were associated with LVH but no difference was
found for heart wall or septum thickness, heart to body weight or heart weight to tibia
length (Supplementary Figure 3.14).
Klotho expression and FRS2a phosphorylation state
Since cy/+ animals appear to be resistant to the expected normal biological actions of
FGF23 we examined whether Klotho availability or FGF23 signaling via the FGFR-1
receptor may be altered. We observed similar relative Klotho mRNA expression in cy/+
and +/+ animals at 2 and 4 weeks whereas at 8 weeks, Klotho mRNA expression was
reduced in cy/+ animals (Figure 3.8a). Klotho protein abundance was similar in 8 weeks
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Figure 3.7: Phosphate and glucose uptake into renal brush border membrane vesicles.
Phosphate uptake without (a) and with (b) PFA and glucose uptake (c) after 2, 4, and 8 weeks
in cy/+ (black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals
(median), cy/+ = 11, +/+ = 7; * p<0.05.
old cy/+ and +/+ animals (Figure 3.8b). Relative mRNA expression levels of FGFR-1
in kidney and bone were similar among cy/+ and +/+ animals (Supplementary Figure
3.15). The downstream signaling of FGF23, Klotho, and FGFR-1 complex leads to the
phosphorylation of the FGF receptor substrate 2 alpha (FRS2a). Total FRS2a was similar
in kidneys from 8 week old cy/+ and +/+ rats, whereas phosphorylated FRS2a protein
was increased (Figure 3.8c).
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Figure 3.8: Klotho expression and phosphorylation state of FRS2a. Relative mRNA
expression of Klotho in kidney (a) to 18S rRNA after 2, 4, and 8 weeks; relative protein expression
of Klotho (b) and phosphorylation state of FRS2a (c) to GAPDH after 8 weeks in cy/+ (black
bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ =
4, +/+ = 4; * p<0.05.
Elevated plasma FGF23 and renal expression of FGF23 in conditional Pkd1
KO mice
We employed a second model of PKD, the conditional Pkd1 KO mice where deletion of
Pkd1 gene can be induced. We induced Pkd1 deletion at days 15-19 after birth which result
in a slow progression of cystic kidney disease [202]. Pkd1 mRNA was strongly reduced in
kidneys and bone from 10 week old Pkd1fl/fl, cre+ mice as compared to Pkd1fl/fl, cre-
mice (Supplementary Figure 3.16). Conditional Pkd1 KO elevated intact FGF23 plasma
levels in 10 weeks old Pkd1fl/fl, cre+ (277 ± 130 pg/ml) compared to Pkd1fl/fl, cre- mice
(199 ± 57 pg/ml) whereas TmP/GFR and creatinine clearance was similar in knockout
and healthy animals (Figure 3.9). Intact PTH did not differ between Pkd1fl/fl, cre+ (176
± 71 pg/ml) and Pkd1fl/fl, cre- (253 ± 126 pg/ml) mice (Figure 3.9). Similar to the rat
model, Pkd1fl/fl, cre+ mice expressed similar FGF23 mRNA levels in bone as the control
mice. Kidneys from Pkd1fl/fl, cre+ mice expressed FGF23 mRNA and protein but not
kidneys from Pkd1fl/fl, cre- (Figure 3.9 and Supplementary Figure 3.17).
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Figure 3.9: FGF23, PTH, TmP/GFR, and renal function in Pkd1fl/fl mice. Plasma
intact FGF23 (a) and PTH (b) as well as TmP/GFR (c) and creatinine clearance (d) after 10
weeks in Pkd1fl/fl, cre+ (black bars) and Pkd1fl/fl, cre- (white bars) mice (mean ±SD); number
of animals (median), Pkd1fl/fl, cre+ = 7, Pkd1fl/fl, cre- = 16; * p¡0.05.
Figure 3.10: FGF23 and Klotho expression in bone and kidneys of Pkd1fl/fl mice.
Relative mRNA expression of FGF23 in kidney (a) and bone (b) as well as Klotho in kidney (c)
to 18S rRNA after 10 weeks in Pkd1fl/fl, cre+ (black bars) and Pkd1fl/fl, cre- (white bars) mice
(mean ±SD), Pkd1fl/fl, cre+ = 8, Pkd1fl/fl, cre- = 15 * p<0.05 and ** p<0.001.
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3.1.4 Discussion
Our study provides four major findings: i) the Han:SPRD rat model accurately repro-
duces the observed increase of FGF23 levels in the early disease course of human ADPKD
with normal kidney function, ii) Han:SPRD rats show resistance to highly elevated FGF23
levels as evident from normal phosphatemia, unchanged renal phosphate excretion, pre-
served expression of renal phosphate cotransporters, increased PTH, normal 1,25(OH)2
vitamin D3 levels, and normal expression of Cyp27b1, iii) expression of FGF23 in poly-
cystic kidneys, and iv) reproduction of the major findings in a second model of ADPKD,
the inducible Pkd1 KO mouse.
ADPKD patients with an estimated GFR of 60 ml/min/1.73m2 and higher display strongly
elevated FGF23 levels but only a small fraction of these patients present a reduction in
renal phosphate reabsorption - albeit small - and a very mild hypophosphatemia [184].
In ADPKD patients with normal renal phosphate handling despite high FGF23 levels,
reduced soluble Klotho levels were found whereas ADPKD patients that appeared to re-
tain sensitivity to high FGF23 levels had preserved soluble Klotho levels [185]. However,
the temporal sequence of rising FGF23 in PKD, the mechanisms underlying resistance to
the biological actions of FGF23, and the source and cause of the elevated FGF23 levels
remained unclear.
Herein, we demonstrate that intact FGF23 concentration in the cy/+ Han:SPRD rats
increases early after birth before renal function decreases. The high FGF23 levels were ac-
companied by a 2-fold increase in PTH and normal 1,25(OH)2 vitamin D3 levels. Plasma
creatinine and urea indicated a decrease in renal function in cy/+ animals 6 weeks after
birth and thereby 4 weeks after the rise in FGF23 and PTH [218] Similarly, the inducible
Pkd1 KO mouse, a second ADPKD model, has elevated plasma FGF23 levels whereas cre-
atinine clearance, TmP/GFR, and intact PTH were normal. Thus, Han:SPRD rats and
Pkd1 KO mice illustrate an increase in FGF23 levels similar to that observed in young
ADPKD patients with preserved renal function, thus allowing to approach the underlying
mechanisms in more detail.
In healthy subjects and animals, a rise in FGF23 results in increased urinary excretion of
phosphate through reduced expression of renal phosphate cotransporters, thus leading to
a lowering of systemic serum phosphate concentrations; concomitant reduction in circu-
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lating levels of active 1,25(OH)2 vitamin D3 levels occurs [47] which may participate in
serum phosphate reduction.
ADPKD patients and the PKD rodent models are resistant to the elevated FGF23 as
indicated by normophosphatemia, normal renal phosphate excretion, unchanged expres-
sion and activity of renal phosphate cotransporters, and apparently normal vitamin D3
metabolism. Moreover, the expression and activity of the main renal phosphate cotrans-
porters NaPi-IIa and NaPi-IIc are unchanged or elevated as indicated by immunoblotting,
transport studies, and immunolocalization whereas in mice, overexpressing FGF23, NaPi-
IIa mRNA and protein expressions are down regulated [226]. No left ventricular hyper-
trophy was detected suggesting either that FGF23 requires longer time periods, stronger
elevation or that the heart is also resistant to high FGF23 levels.
Vitamin D3 metabolism is similar in polycystic and control rats: indeed plasma 1,25(OH)2
vitamin D3 concentrations and mRNA expression of Cyp27b1 did not differ between both
groups of animals. Cyp24a1 was upregulated at 2 weeks in PKD animals which could be
due to an early rise of plasma FGF23 concentration, but this effect was only transient and
not observed at later time points.
We further investigated underlying mechanisms of resistance and found normal expression
of the FGFR-1 receptor mediating the biological effects of FGF23 in the kidney [69, 85].
Mice constitutively expressing FGF23 have no changes in FGFR-1 expression levels sug-
gesting that FGF23 per se does not modulate FGFR-1 expression [226]. Klotho is required
to elicit FGF23 signals via the FGFR1 receptor [69]. In our PKD model Klotho protein
abundance was unchanged. The activation of the Klotho/FGFR-1 complex leads to the
phosphorylation of FRS2a. In the HanSPRD model pFRS2a was increased in cy/+ kidneys
suggesting that FGF23 signaling can be induced but may be blocked further downstream.
PKD animals have also higher PTH levels than control animals which are in contrast to
ADPDK patients with normal eGFR [184]. The elevation of PTH levels was also observed
in other CKD rat models and may be due to the faster disease progression in animals
compared with humans [157, 161]. Measurement of plasma PTH at shorter intervals
or studies in another animal model with slower disease progression might overcome this
gap. FGF23 suppresses PTH secretion in healthy rats but loss of Klotho expression in
parathyroid glands may be involved in the induction of FGF23 resistance and secondary
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hyperparathyroidism [91, 93].
We further analyzed the source(s) of elevated FGF23 by examining FGF23 mRNA ex-
pression in different organs such as bone as the major source of FGF23 in health, spleen,
kidney, heart, and liver. In wildtype animals, we detected FGF23 mRNA expression
mainly in bone, and very small amounts were also observed in spleen, whereas PKD rats
and mice expressed FGF23 mRNA and protein also in the polycystic kidneys more pre-
cisely in the cells lining the cysts. In the rat and mouse PKD animal models FGF23
mRNA expression levels increased only in the polycystic kidneys whereas bone expressed
similar mRNA levels in both groups suggesting that kidney may be the major source of
elevation of FGF23 levels in PKD. Similarly, in diabetic nephropathy the kidney may
become a source of FGF23 [227]. The mechanisms causing ectopic FGF23 expression in
kidney are currently unknown. Interestingly, the kidney expresses several regulators of
FGF23 secretion in bone such as Dmp1 and Fam20c and we found upregulation of Dmp1
in polycystic kidneys. In diabetic nephropathy, renal FGF23 expression was suppressed
by ACE inhibition [227]. Several rodent models have been reported with elevated FGF23
levels induced by deletion of the OSR1 and SPAK protein kinases expressed in kidney
[228, 229]. Whether these kinases contribute to elevated FGF23 levels in ADPKD models
remains to be elucidated.
In summary, we found 10-fold elevated FGF23 levels in PKD animals and resistance of
the target organs to its biological actions at early stage of polycystic kidney disease. The
polycystic kidney may be a major source of FGF23 in this type of nephropathy.
3.1.5 Methods
Animals
The Han:SPRD rat colony was established in our animal facility from a litter which was ob-
tained from the Rat Resource and Research Center (Columbia, MO) [223]. Male heterozy-
gous cystic (cy/+) and wild-type (+/+) rats were used in this study. Pkd1 floxed/floxed
(Pkd1fl/fl) tamoxifen inducible cre mice were kindly provided by Gregory Germino [201].
Male and female Pkd1fl/fl cre+ and Pkd1fl/fl cre- mice were used. We induced recombi-
nase activity at days 15, 17, and 19 by injecting pups with 100 µl tamoxifen (2.5mg/ml) in
corn oil. All animal studies were performed according to protocols approved by the legal
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authority (Veterinary Office of the Canton of Zurich).
Plasma and urine analysis
Blood and spot urine was collected from cy/+ and +/+ control rats at week 2, 4, 6, and
8 after birth. Some rats included in the week 6 group were sacrificed between 5 and 6
weeks after birth. Plasma and urine aliquots were rapidly frozen and stored at -80◦C until
measurement. Plasma concentrations of phosphate, calcium, and urea and urinary concen-
trations of phosphate and calcium were measured by the Institute of Clinical Chemistry
at the University Hospital Zurich using standard methods. Pkd1fl/fl mice were fasted
overnight before urine was collected for six hours in metabolic cages (Tecniplast R©, Italy).
Afterwards the mice were anesthetized with isoflurane and blood was collected from the
heart. Urine and plasma laboratory analysis were performed by the Zurich Integrative
Rodent Physiology (ZIRP) core facility.
The ratio of the maximum rate of tubular phosphate reabsorption to the glomerular fil-
tration rate (TmP/GFR) was calculated as follows:
TmP/GFR in mmol/L = PP − [UP × Pcrea/Ucrea]
where PP , UP , Pcrea , and Ucrea refer to the plasma and urinary concentration of phos-
phate and creatinine, respectively [230]. The fractional excretion of calcium was calculated
according to the following equation:
FECa = (UCa × Pcrea)/(PCa × Ucrea)× 100
where PCa, UCa, Pcrea, and Ucrea refer to the plasma and urinary concentrations of cal-
cium and creatinine, respectively. The plasma concentration of intact FGF23 (Kainos
Laboratories, Tokyo, Japan), intact PTH (Immutopics International, California, USA)
and 1,25(OH)2 vitamin D3 (Immunodiagnostic Systems, London, UK) were measured by
enzyme-linked immunosorbent assays according to the manufacturer’s protocols.
RNA extraction and RT-PCR
Rats were sacrificed at week 2, 4, and 8 for harvesting kidney, bone, liver, spleen, and
heart. Mice were sacrificed at week 10 for harvesting kidneys and bone. The organs were
rapidly frozen in liquid nitrogen. Total RNA was extracted using the Qiagen RNeasy Mini
Kit (Qiagen, Hombrechtikon, Switzerland) or TRizol reagent for bone tissue (Invitrogen,
Zug, Switzerland). Snap-frozen tissue slices were homogenized in a pestle homogenizer
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(Potter-Elvehjem type) together with 1ml precooled RLT-Buffer supplemented with β-
mercaptoethanol at a final concentration of 1%. Subsequently, 700 µl of the homogenate
were used for RNA preparation, which was carried out according to the manufacturer’s
protocol. DNAse digestion was performed using the RNase-free DNAase Set (Qiagen;
Hilden, Germany). Total RNA extractions were analyzed for quality, purity, and concen-
tration using the NanoDrop ND-1000 spectrophotometer (Wilmington, DE, USA). RNA
samples were diluted to a final concentration of 100 ng/µl and cDNA was prepared using
the TaqMan Reverse Transcriptase Reagent Kit (Applied Biosystems, Roche; Forster City,
CA, USA). In brief, in a reaction volume of 40 µl, 300 ng of RNA was used as template
and mixed with the following final concentrations of RT buffer (1x), MgCl2 (5.5 mM),
random hexamers (2.5 µM), dNTP mix (500 µM each), RNase inhibitor (0.4 U/µl), mul-
tiscribe reverse transcriptase (1.25 U/µl) and RNAse-free water. Reverse transcription
was performed with thermocycling conditions set at 25◦C for 10 min, 48◦C for 30 min,
and 95◦C for 5 min on a thermocyler (Biometra, Goettingen, Germany). Quantitative
real-time PCR (qRT-PCR) was performed on the ABI PRISM 7700 Sequence Detection
System (Applied Biosystems). Primers for all genes of interest (Supplementary Table 1)
were designed using Primer Express software from Applied Biosystems. Primers were
chosen to result in amplicons no longer than 150 bp spanning intron-exon boundaries to
exclude genomic DNA contamination. The specificity of all primers was first tested on
mRNA derived from kidney, bone or intestine and always resulted in a single product of
the expected size (data not shown). Probes were labelled with the reporter dye FAM at
the 5’-end and the quencher dye TAMRA at the 3’-end (Microsynth, Balgach, Switzer-
land). Real-Time PCR reactions were performed using TaqMan Universal PCR Master
Mix (Applied Biosystems) as described [211].
32P and 3H-glucose-uptake in brush border membrane vesicles
Brush border membrane vesicles were prepared using the Mg2+-precipitation technique
[231, 232] and further used for western blotting and transport studies. The transport rate
of 32-labeled phosphate and tritium labeled glucose into renal brush border membrane
vesicles was determined at 30 s and 120 min (equilibrium value) as described [231] at
25◦C in the presence of inward gradients of 100 mM NaCl or 100 mM KCl and 0.1 mM
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K2HPO4. All measurements were performed in triplicates.
Western blot analysis
After measurement of the protein concentration (Bio-Rad, Hercules, CA), 10 µg of renal
brush border membrane for NaPi-IIa and NaPi-IIc and 20 µg or 2 µg, respectively, of
total kidney homogenate for FRS2a/pFRS2a and Klotho was solubilized in loading buffer
containing DTT and separated on 8% polyacrylamide gels. For immunoblotting, proteins
were transferred electrophoretically to polyvinylidene fluoride membranes (Immobilon-
P, Millipore, Bedford, MA, USA). After blocking with 5% milk powder in Tris-buffered
saline/0.1% Tween-20 for 60 min, blots were incubated with the primary antibodies: rabbit
polyclonal anti-NaPi-IIa (1:6000) [27, 233], rabbit polyclonal anti-NaPi-IIc (1:10000) [211],
mouse monoclonal anti-β-actin antibody (42kD; Sigma, St. Louis, MO; 1:5000), mouse
monoclonal anti-FRS2a (R&D Systems, USA; 1:1500), rabbit polyclonal anti-pFRS2a
(Cell Signaling Technology, USA; 1:2000), rat monoclonal anti-Klotho (Clone KM2076,
TransGenic Inc., Japan; 1:1000), and mouse monoclonal anti-GAPDH (Merck Millipore,
USA; 1:20000) either for 2 h at room temperature or overnight at 4◦C. Membranes were
then incubated for 1 h at room temperature with secondary goat anti-rabbit, donkey
anti-mouse or goat anti-rat antibodies (1:5000) linked to alkaline phosphatase (Promega,
USA), HRP (Amersham, USA or R&D Systems, USA). The protein signal was detected
with the appropriate substrates using the DIANA III-chemiluminescence detection sys-
tem (Raytest, Straubenhardt, Germany). All images were analyzed using the software
Advanced Image Data Analyser AIDA, Raytest to calculate the protein of interest/actin
ratio.
Immunofluorescence staining
Rat kidneys were perfused in situ through the left heart ventricle with a fixative solution
containing 3% paraformaldehyde in phosphate buffered saline (PBS). Mouse kidneys were
immersed in a fixative solution containing formalin (10%). Kidneys were embedded in
TissueTec and frozen in liquid nitrogen cooled by liquid propane. Five µm cryosections
were cut. Slides were washed in PBS and incubated in 50 mM NH4Cl in PBS for 20 min
at room temperature to reduce free aldehyde groups. For FGF23 staining, slides were
treated for 5 min with 0.5% SDS in PBS. Unspecific sites were blocked with 1% bovine
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serum albumin (BSA) in PBS for 1 h at room temperature. Primary antibodies were
diluted in 1% BSA in PBS (NaPi-IIa 1:1000; anti-FGF23 (R&D Systems, USA) 1:1000;
anti-Calbindin (Swant, Switzerland) 1:20000) and kidney sections were incubated with
the primary antibody over night at 4◦C. After washing with PBS, sections were incu-
bated with the corresponding secondary antibody (1:500) (anti-rabbit Alexa594 (Invitro-
gen, Switzerland), anti-rat NL493 (R&D Systems, USA); anti-mouse (DyLight 649, Jack-
son ImmunoResearch, Europe), phalloidin-FITC (1:200), and DAPI (Invitrogen,1:1000)
for 1 h at room temperature. Slides were washed twice with PBS before being mounted
with Dako glycergel mounting medium. Sections were visualised on a Leica DM 5500B
fluorescence microscope and images processed with Adobe Photoshop CS5 extended.
Statistical analysis
Statistics were performed using unpaired Student‘s t-test (GraphPad Prism version 5.0,
GraphPad, San Diego, CA). Random-effects models for longitudinal data were applied
to analyse unbalanced repeated measures (SAS version 9.3, Cary, NC, USA). Data are
provided as mean ± SD. P < 0.05 was considered significant.
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3.1.8 Supplementary Data
Supplementary Methods
H&E staining
Hearts were fixed in 10% buffered formalin over night and embedded in paraffin. Sections
were stained with Hematoxilin-Eosin following routine protocols.
Supplementary Figures
Figure 3.11: Renal function after fasting overnight of 4 weeks old HanSPRD rats.
Plasma phosphate (a), plasma total calcium (b), TmP/GFR (c), and creatinine clearance after 4
weeks in cy/+ (black bars) and +/+ (white bars) HanSPRD rats (mean ±SD); number of animals
(median), cy/+ n = 12, +/+ n = 8
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Figure 3.12: mRNA expression of FGF23 regulatory molecules in kidney and bone.
Relative mRNA expression of Fam20c and Dmp1 in kidney (a, c) and bone (b, d) after 4 and 8
weeks in cy/+ (black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals
(median), cy/+ n = 7, +/+ n = 5; * p<0.05
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Figure 3.13: Immunolocalization of NaPi-IIa. Frozen kidney sections were stained with
antibodies against NaPi-IIa (red), Phalloidin-FITC for actin (green), and DAPI (blue) in cy/+
and +/+ animals after 4 and 8 weeks. Scale bar 50 µm.
Figure 3.14: Heart wall thickness and heart weight. Heart wall (a) and septum thickness
(c) of 4 weeks old HanSPRD rats; heart weight of 10 weeks old rats normalized to body weight (b)
and tibia length (d); number of animals (median), cy/+ = 5, +/+ = 4
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Figure 3.15: FGFR-1 mRNA expression. Relative mRNA expression of the FGF receptor 1
(FGFR-1) in bone (a) and kidney (b) to 18S rRNA after 2, 4, and 8 weeks in cy/+ (black bars)
and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ n = 6,
+/+ n = 5
Figure 3.16: Pkd1 mRNA expression. Relative Pkd1 mRNA abundance in kidney (a) and
bone (b) of 10 weeks old Pkd1fl/fl, cre+ (black bars) compared to Pkd1fl/fl, cre- (white bars)
mice (mean ±SD); number of animals (median), Pkd1fl/fl, cre+ n = 8, Pkd1fl/fl, cre- n = 15; **
p<0.001
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Figure 3.17: Expression of FGF23 in kidneys from Pkdfl/fl, cre+ KO mice. Frozen
kidney sections were stained for FGF23 (green), calbindin D28k, a marker of DCT and CNT
segments (red), and DAPI (cell nuclei). In kidneys from Pkd1fl/fl, cre+ mice strong FGF23
staining is observed in cells lining the cysts (a,b), no staining for FGF23 is observed in kidneys
from Pkd1fl/fl, cre- mice (c,d). Omission of primary antibodies in Pkd1fl/fl, cre+ kidneys showed
no staining (e). Original magnification 400 x.
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Table 3.1: Primer and probe sequences used for RT-PCR
Gene Type Sequence
Rat NaPi-IIa Fwd 5’-GGAATCACAGTDTCATTCGGATT-3’
(Slc34a1) Rev 5’-ATGGCCTCTACCCTGGACATAG-3’
Probe 5’-TGTCAACCAGAGACAAAAGAGGCTTCCACT-3’
Rat NaPi-IIc Fwd 5’-GGGATCGGGATGAATTTCAGA-3’
(Slc34a3) Rev 5’-GGGCCAGCTCACTCAGTCTCT-3’
Probe 5’-ACGGCATCTTCAACTGGCTCACAGTGTT-3’
Rat FGF23 Fwd 5’-GCAACATTTTTGGATCGTATCA-3’
Rev 5’-GATGCTTCGGTGACAGGTAGA-3’
Probe 5’-AGATTCCGCCAGTGGACGCTAGAGA-3’
Rat Klotho Fwd 5’-TATCTCAAGAAGTTCATAATGGAAAGC-3’
Rev 5’-GAGGGACCATGCGGTGTA-3’
Probe 5’-TAAAAGCCATCAGGCTGGATGGGG-3’
Rat FGFR1 Fwd 5’-GGTTGAAAAATGGCAAGGAA-3’
Rev 5’-CCACGATGCAGGTGTAGTTG-3’
Probe 5’-TCGGAGGCTACAAGGTTCGTTACGC-3’
Rat Cyp24a1 Fwd 5’-CAAATCAGTCAAACCCTGCAT-3’
Rev 5’-GGCGTACAGTTCCTTCTTGG-3’
Probe 5’-TACAGAGATATTCCCAGCAGCCCGG-3’
Rat Cyp27b1 Fwd 5’-TGGCAAACGAAGTTGCATAG-3’
Rev 5’-AGCACCTCAAAATGGGTCAA-3’
Probe 5’-CTACAAATGGCGTTGGCCCAGATC-3’
Rat Fam20c Fwd 5’-CCATCGATGCCTTACTCCAC-3’
Rev 5’-CCCGTAATTCTGGAAGGTCA-3’
Probe 5’-CAGAAGATCACCAGTGTCGCCATGA-3’
Rat Dmp1 Fwd 5’-CTGTCCTGTGCTCTCCCTGT-3’
Rev 5’-GCTGTCCGTGTGGTCACTATT-3’
Probe 5’-TCTGAAAGCTCCGAAGAGAGGACGG-3’
Mouse Pkd1 Fwd 5’-GGCCAACCTCTCCTCAGTATC-3’
Rev 5’-GAAGGGTACTGCTGCCACA-3’
Probe 5’-CTGTGGTGAGGAATATGTCGCCTGC-3’
Mouse FGF23 Fwd 5’-TCGAAGGTTCCTTTGTATGGAT-3’
Rev 5’-AGTGATGCTTCTGCGACAAGT-3’
Probe 5’-TTTTTGGATCGCTTCACT-3’
Mouse Klotho Fwd 5’-ACGTTCAAGTGGACACTACTCTCTC-3’
Rev 5’-TTGGCTACAACCCCGTCTAC-3’
Probe 5’-CCGAATGTCTATCTGTGGGATGTGCA-3’
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3.2 Inflammation triggers renal expression of FGF23 and
elevates systemic FGF23 levels in polycystic kidney dis-
ease
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3.2.1 Abstract
Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is directly
linked to all-cause mortality in chronic kidney disease (CKD). In polycystic kidney dis-
ease (PKD) animal models plasma Fgf23 rises, however, Fgf23 expression in bone is
unchanged instead of the kidney becomes a site of Fgf23 production. Since polycystic
kidneys experience local hypoxia and inflammation, we examined whether hypoxia or in-
flammation affect Fgf23 expression in bone and polycystic kidneys. PKD kidneys had
increased Tnfα and Tgfβ expression as well as increased phosphorylation of the NfκB sub-
unit p65. Tnfα/NfκB signaling increases Nurr1 expression, an orphan nuclear receptor
involved in the Pth dependent regulation of Fgf23 expression in bone. In PKD kidneys,
Nurr1 expression was upregulated and Nurr1 protein was predominantly localized in the
cell nucleus. Nuclear Nurr1 overlapped with Fgf23 expression in the kidneys of PKD mice.
Tnfα but not hypoxia stimulated Fgf23 expression in primary mouse osteocytes and was
paralleld by changes in Nurr1 expression. Antibody-mediated neutralization of Tnfα in
Pkd1 conditional KO mice reduced renal Tnfα and Tgfβ mRNA expression and concomi-
tantly decreased plasma Fgf23 levels. In conclusion, ectopic renal Fgf23 expression is
triggered by Tnfα and Tnfα blockade normalizes expression of osteogenic markers and
regulators of FGF23 expression in kidney along with plasma Fgf23 levels in PKD animals.
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3.2.2 Introduction
Fibroblast growth factor 23 (Fgf23) is critical to maintain phosphate homeostasis and vi-
tamin D3 metabolism [59, 60]. The main target organ of Fgf23 is the kidney where Fgf23
binds in the presence of its obligate co-factor Klotho to the FGFR receptor and inhibits
phosphate reabsorption as well as decreases 1,25(OH)2 vitamin D3 levels by reducing its
synthesis and accelerating its degradation [69, 77]. Fgf23 is mainly expressed in bone and
to a lower extent in thymus, spleen, brain, and heart [59, 61, 62, 65].
Many systemic factors regulate Fgf23 gene expression among them 1,25(OH)2 vitamin D3,
Pth as well as inflammatory cytokines such as TNFα and IL-1β [63, 130, 131, 133, 147].
In bone, 1,25(OH)2 vitamin D3 activates and translocates the vitamin D (VDR) receptor
to the nucleus where it binds in form of the VDR/RXR heterodimeric complex to the vi-
tamin D response element in the Fgf23 promoter region and stimulates Fgf23 expression
[54–56, 63]. Pth has an other mode of action by which it activates the G protein coupled
receptor PTHR on bone cells [134, 135]. This leads to a cAMP dependent activation of
protein kinase A (PKA) and the subsequent induction of the nuclear receptor related 1
protein (Nurr1) expression [134, 135]. Nurr1 belongs to the nuclear orphan receptor family
and is an early response gene which regulates target genes by binding to the nerve growth
factor B response element (NBRE) in their promoter region [234–236]. Nurr1 physically
interacts with the NBRE sequence in the FGF23 promoter region and activates Fgf23 gene
expression in UMR-106 rat osteosarcoma cells [133]. Apart from Pth, various factors such
as membrane depolarization, brain and liver ischemia, as well as inflammatory cytokines
such as tumor necrosis factor α (Tnfα) and interleukin 1β (IL-1β) stimulate Nurr1 ex-
pression and are therefore potential regulators of Fgf23 expression [234, 237–239]. Indeed,
Tnfα, Il-1β, as well as lipopolysaccaride (LPS) stimulation increases Fgf23 expression in
IDG-SW3 osteocyte cells, macrophages, and dendritic cells [147, 149].
Chronic kidney disease (CKD) leads to a severe disturbance of mineral homeostasis which
is one of the leading factors for morbidity and mortality in patients with endstage renal
disease [155]. In the course of CKD, FGF23 levels rise before PTH and plasma phosphate
concentrations and are independently associated with mortality [156, 157, 166]. The sub-
sequent change of parameters of mineral homeostasis can be reproduced in the Col4a3−/−
mouse, a CKD animal model [160]. The early rise of serum Fgf23 levels in Col4a3−/− mice
59
is not accompanied by an increase in Fgf23 gene expression in bone [160]. Interestingly,
ectopic Fgf23 gene and protein expression was reported in the kidneys of rats with diabetic
nephropathy as well as in kidneys from animals with polycystic kidney disease (PKD), two
models of CKD [227, 240]. The trigger for renal Fgf23 expression is so far unknown.
In this study we evaluated hypoxia and inflammation, two common denominators of di-
abetic nephropathy and PKD, as possible factors regulating Fgf23 expression in kidneys
of Pkd1 conditional KO mice as well as in bone cell culture models.
3.2.3 Results
Kidney weight, Pkd1 knockdown and phosphate homeostasis
Cre recombinase activity of Pkd1 conditional KO mice was activated by injection of ta-
moxifen (0.25mg/animal) at postnatal days 15, 17, and 19 to induce a slow PKD disease
progression model [202]. At week 6, Pkd1fl/fl, cre+ animals had a two kidney per body
weight (BW) ratio of 16 ± 2 mg/g BW which was similar compared to Pkd1fl/fl, cre-
animals (13 ± 1 mg/g BW) (Figure 3.18a). The two kidney per body weight ratio was
dramatically increased in Pkd1fl/fl, cre+ animals (68 ± 36 mg/g BW) at week 12 due to
massive bilateral cyst growth. After 6 and 12 weeks 19% and 74% residual Pkd1 expres-
sion, respectively, was detected in Pkd1fl/fl, cre+ animals compared to Pkd1 expression
in Pkd1fl/fl, cre- animals at week 6 (Figure 3.18 b) consistent with previous reports of
compensatory increase of remaining Pkd1 expression in cystic epithelial cells [241].
Plasma Fgf23 and Pth levels were similar in Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- animals
after 6 weeks (Figure 3.18 c and d). At week 12, plasma Fgf23 levels were significantly
higher in Pkd1fl/fl, cre+ (255 ± 192 pg/ml) compared to Pkd1fl/fl, cre- animals (87 ±
23 pg/ml). To the contrary, serum Pth levels decreased significantly after 12 weeks in
Pkd1fl/fl, cre+ (57 ± 19 pg/ml) compared to Pkd1fl/fl, cre- animals (237 ± 124 pg/ml).
The ratio of maximal rate of tubular phosphate reabsorption per glomerular fitration rate
(TmP/GFR) and blood urea nitrogen (BUN) did not differ between Pkd1fl/fl, cre+ and
Pkd1fl/fl, cre- animals at week 6 (Figure 3.18 e and f). At week 12, TmP/GFR was
significantly decreased in Pkd1fl/fl, cre+ (4.6 ± 1.1 mg/dl) compared to Pkd1fl/fl, cre-
animals (6.3 ± 1.2 mg/dl) whereas at the same time point BUN significantly increased in
Pkd1fl/fl, cre+ (148 ± 60 mg/dl) compared to Pkd1fl/fl, cre- animals (60 ± 7 mg/dl).
60
There was no difference in the creatinine clearance between Pkd1fl/fl, cre+ and Pkd1fl/fl,
cre- animals at any time point studied (Figure 3.18 g). Taken together, these data indicate
a state of chronic kidney disease in the 12 weeks old animals.
Renal expression of bone marker genes
We had previously reported renal Fgf23 mRNA and protein expression in 10 weeks old
Pkd1fl/fl, cre+ animals [240]. Here, Pkd1fl/fl, cre+ animals at week 6 and Pkd1fl/fl, cre-
animals at week 6 and 12 did not express Fgf23 mRNA or protein whereas Pkd1fl/fl, cre+
animals at week 12 had a significant increase in renal Fgf23 mRNA expression (Figure
3.19 a). At the same time Fgf23 mRNA expression in bone was similar in Pkd1fl/fl, cre+
and Pkd1fl/fl, cre- animals (Figure 3.19 b). Osteogenic marker genes such as Runx2 and
Dmp-1 were upregulated in kidneys of Pkd1fl/fl, cre+ compared to Pkd1fl/fl, cre- animals
(Figure 3.19 c and e). The same genes were similarly expressed in bones of Pkd1fl/fl, cre+
and Pkd1fl/fl, cre- animals (Figure 3.19 d and f).
Inflammation in PKD kidneys
Renal FGF23 expression was also reported in rats with diabetic nephropathy [227]. Two
common denominators of diabetic nephropathy and PKD are local renal hypoxia and in-
flammation [242–247]. Moreover, hypoxia stimulated Fgf23 expression in the UMR-106
rat osteosarcoma cell line [139]. Therefore we evaluated these two factors as potential
triggers for renal and bone FGF23 expression. First, we assessed the presence of inflam-
mation markers in the kidney. At week 6, renal Tnfα and Tgfβ mRNA expression was
similar in Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- animals (Figure 3.20 a and b). In the course
of PKD disease, Tnfα and Tgfβ mRNA expression increased significantly in Pkd1fl/fl,
cre+ animals compared to Pkd1fl/fl, cre- animals (Figure 3.20 a and b). Tnfα binding
to Tnfα receptors activates the NfκB signaling pathway [248]. Figure 3.20 c shows the
phosphorylation state of the NfκB subunit p65 as well as total NfκB p65 protein in the
nuclear fraction of total kidney homogenates. The ratio of Phospho-NfκB p65 to NfκB
p65 was significantly elevated in the kidneys of Pkd1fl/fl, cre+ compared to Pkd1fl/fl,
cre- animals.
61
Figure 3.18: Baseline characteristics of Pkd1 KO mice. Two kidney per body weight ratio
(a), Pkd1 mRNA expression normalized to Pkd1fl/fl, cre- mice (6 weeks) (b), plasma Fgf23 (c),
plasma Pth (d), TmP/GFR (e), BUN (f), and creatinine clearance (g) in Pkd1fl/fl, cre+ (black
squares) and Pkd1fl/fl, cre- (white squares) animals at the age of 6 and 12 weeks, respectively
(mean ±SD). Number of animals per group 6-9; * p<0.05, ** p<0.0001.
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Figure 3.19: Expression of bone marker genes in kidney and bone of Pkd1 KO mice.
Fgf23 (a, b), Runx2 (c, d), and Dmp-1 (e, f) mRNA expression relative to 18S rRNA in kidney
and bone of Pkd1fl/fl, cre+ (black squares) and Pkd1fl/fl, cre- (white squares) animals at the
age of 6 and 12 weeks, respectively (mean ±SD). Number of animals per group 6-9; * p<0.05, **
p<0.0001.
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Figure 3.20: Inflammation markers in the kidney of Pkd1 KO mice. Renal Tnfα (a) and
Tgfβ (b) mRNA expression relative to 18S rRNA in Pkd1fl/fl, cre+ (black bars) and Pkd1fl/fl,
cre- (white bars) animals at the age of 6 and 12 weeks, respectively. Phosphorylation state of NfκB
in the nuclear fraction of total kidney protein homogenates in Pkd1fl/fl, cre+ (black bars) and
Pkd1fl/fl, cre- ( white bars) animals after 12 weeks (mean ±SD). Number of animals per group
6-9; * p<0.05, ** p<0.0001.
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Expression and localization of Nurr1 in polycystic kidneys
The orphan nuclear receptor Nurr1 activates Fgf23 mRNA expression in rat osteosarcoma
cells [133]. Nurr1 expression itself is stimulated by NfκB in response to Tnfα [239]. Nurr1
mRNA was detected in mouse kidney and bone (Figure 3.21). At week 6, renal Nurr1
expression was similar in Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- animals. At week 12, renal
Nurr1 expression was significantly increased in Pkd1fl/fl, cre+ whereas Nurr1 expression
in bone was similar in PKD and control animals (Figure 3.21 a and b). Nurr1 is a orphan
nuclear receptor and is active upon translocation to the nucleus where it binds to NERB
sequences in the promotor region of target genes [234–236]. We found that Nurr1 in
Pkd1fl/fl, cre+ kidneys was predominantly localized in the cell nucleus whereas Nurr1 in
Pkd1fl/fl, cre- animals was mainly distributed in the cytoplasm (Figure 3.21 c to j and
Supplementary Figures 3.24 and 3.25). Further, nuclear Nurr1 staining in Pkd1fl/fl, cre+
animals is often but not exclusively co-localized with Fgf23 expressing cells. There was no
Fgf23 protein expression in Pkd1fl/fl, cre- animals. Staining of tissue section only with
secondary antibodies revealed no staining (Figure 3.21 k).
Tnfα but not hypoxia stimulates Fgf23 expression in bone cells
We cultured primary osteocytes from tibias and femurs of mice according to established
protocols [249, 250]. Cells from digestion step 6-9 or cells and bone pieces from diges-
tion step >9 expressed markers of osteocytes and were cultured for 2 weeks in osteogenic
medium before supplemented for 24 hours either with 10 ng/ml Tnfα or 10 nM 1,25(OH)2
vitamin D3. Tnfα as well as 1,25(OH)2 vitamin D3 increased Fgf23 mRNA expression in
primary osteocytes (Figure 3.22 a). Further we investigated the expression of regulators
of Fgf23 gene expression or postranslational processing of Fgf23. Tnfα but not 1,25(OH)2
vitamin D3 increased the expression of the orphan nuclear receptor Nurr1 as well as the
expression of Galnt3 (Figure 3.22 b and c). Galnt3 is important for the O-glycosylation
of FGF23 preventing proteolytic cleavages of Fgf23 [102–105]. The expression of Bmp-
1, involved in Dmp-1 cleavage, is moderately upregulated by 1,25(OH)2 vitamin D3 but
not by Tnfα (Figure 3.22 d). Binding of Dmp-1 to the extracellular domain of Phex in-
hibits Fgf23 gene expression [123, 125]. Upon Tnfα and 1,25(OH)2 vitamin D3 treatment
Dmp-1 expression was strongly decreased whereas Phex expression was only decreased by
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Figure 3.21: Expression and localization of Nurr1 in the kidney of Pkd1 KO animals.
Nurr1 mRNA expression relative to 18S rRNA in kidney (a) and bone (b) of Pkd1fl/fl, cre+ (black
squares) and Pkd1fl/fl, cre- (white squares) animals at the age of 6 and 12 weeks, respectively.
Number of animals per group 6-9; * p<0.05, ** p<0.0001. Immunofluorescense staining for FGF23
(green), Nurr1 (red), and DAPI (blue, cell nuclei): (c-f) kidneys from 12 weeks old Pkd1fl/fl, cre+
mice, (g-j) kidneys from 12 weeks old Pkd1fl/fl, cre- mice, (k) kidney from 12 weeks old Pkd1fl/fl,
cre+ mice incubated with secondary antibodies alone. Original magnification (c, d, g, h, k) 400x
(scale bar 50 µm) and (e, f, i, j) 1000x (scale bar 20 µm).
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1,25(OH)2 vitamin D3 but not by Tnfα (Figure 3.22 e and f).
MC3T3-E1 mouse preosteoblasts, used to study the effect of hypoxia, did not display
intrinsic Fgf23 expression. Nevertheless, after 2 or 3 weeks differentiation of MC3T3-E1
along the osteogenic lineage Fgf23 mRNA expression was induced by 10 nM 1,25(OH)2
vitamin D3. However, 1,25(OH)2 vitamin D3 induced Fgf23 mRNA expression was com-
pletely repressed when cells were cultured for 24 or 48 hours under hypoxic conditions
(0.2% O2) (Supplementary Figure 3.26 a). The two Hif1α target genes carbonic anhydrase
9 (Ca9) and prolyl hydroxylase domain containing protein 2 (Phd2) were upregulated in
hypoxia and therefore confirmed the presence and effect of hypoxia (Supplementary Figure
3.26 b and c). Similarly, we did not see any effect of hypoxia on Fgf23 mRNA expres-
sion in U2OS rat osteosarcoma cells as well as in primary osteoblast cells (not shown).
Moreover, we evaluated Fgf23 as Hif1α or Hif2α target gene by analyzing kidneys of Von
Hippel-Lindau (Vhl) KO animals [251]. Lack of Vhl protein prevents Hif hydroxylation
and degradation and activates hypoxia sensitive genes [252]. We quantified Fgf23 expres-
sion in kidneys of Vhl KO animals as well as in primary kidney cells lacking Vhl but
neither the kidneys of Vhl KO animals nor the cells lacking Vhl expressed Fgf23 (not
shown).
TNFα blockade in Pkd1 KO mice suppresses Fgf23
In a next step we investigated the effect of Tnfα blockade on Fgf23 expression in PKD
kidneys and plasma. We injected a single dose of 0.5 mg anti-Tnfα antibody or isotypic
IgG control into 12 weeks old Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice. After 24 hours,
anti-Tnfα treated animals had a significant reduction of plasma Tnfα levels compared
to the IgG control treated animals (Figure 3.23 a). There was no difference in plasma
Tnfα levels between IgG control treated Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- animals.
In Pkd1fl/fl, cre+ animals, the reduction of plasma Tnfα was paralleled by a decrease
in renal Tnfα and Tgfβ mRNA expression (Figure 3.23 b and c). Importantly, plasma
Fgf23 levels were significantly decreased in anti-Tnfα treated Pkd1fl/fl, cre+ (215 ± 79
pg/ml) and Pkd1fl/fl, cre- (177 ± 24 pg/ml) compared to IgG treated Pkd1fl/fl, cre+
(326 ± 71 pg/ml) and Pkd1fl/fl, cre- animals (281 ± 32 pg/ml), respectively (Figure 3.23
d). Furthermore renal Fgf23 as well as Nurr1 mRNA expression in anti-Tnfα treated
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Figure 3.22: Regulation of Fgf23 in Tnfα and 1,25(OH)2 vitamin D3 stimulated pri-
mary mouse osteocytes. Fold increase of Fgf23 (a), Nurr1 (b), Galnt3 (c), Bmp-1 (d), Dmp-1
(e), and Phex (f) mRNA expression compared to 18S rRNA in primary mouse osteocytes treated
with 10 ng/ml Tnfα (black squares) or 1,25(OH)2 vitamin D3 (white squares) for 24 hours (mean
±SD). Single experiments were normalized to their untreated control (dashed line = 1). Number of
independent experiments 9-10; * p<0.05, ** p<0.0001 compared to 1,25(OH)2 vitamin D3 treated
cells, # p<0.05, ## p<0.0001 compared to untreated cells.
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Pkd1fl/fl, cre+ animals showed a trend to be suppressed by treatment (Figure 3.23 e and
f).
Figure 3.23: The effect of Tnfα neutralization on Fgf23 in Pkd1 KO mice. Plasma
Tnfα (a) and Fgf23 (d) levels as well as renal mRNA expression of Tnfα (b), Tgfβ (c), Fgf23 (e),
and Nurr1 (f) 24 hours after injection of 0.5 mg anti-TNFα neutralizing antibody or isotypic IgG
control, respectively, in Pkd1fl/fl, cre+ (black squares) and Pkd1fl/fl, cre- (white squares) at the
age of 12 weeks. Number of animals per group 5-8; * p<0.05, ** p<0.0001.
3.2.4 Discussion
This study provides new insights into the abnormal regulation of renal Fgf23 expression
in the Pkd1 conditional KO mouse model and suggests that the proinflammatory cytokine
Tnfα triggers renal Fgf23 expression in PKD kidneys and affects plasma Fgf23 levels.
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The decrease of renal function in the course of CKD entails stepwise changes in mineral
homeostasis [156, 157]. FGF23 rises very early in CKD disease and precedes changes in
serum PTH and phosphate levels [157, 158]. In patients with end stage renal disease,
serum FGF23 levels are associated with mortality independently of serum phosphate lev-
els suggesting that FGF23 is an important disease modulator [166]. In Col4a3−/− KO
mice, a CKD animal model, the changes of parameters of mineral homeostasis occur in
the same chronology as in humans [160]. Interestingly, the early rise in plasma FGF23 is
not accompanied by an increase in Fgf23 expression in bone, the main site of Fgf23 pro-
duction [160]. Similarly, our PKD animal model displayed elevated serum FGF23 levels
while Fgf23 expression in bone was unchanged. The cause for higher Fgf23 levels in CKD
has remained enigmatic. Several factors such as increased production by bone as well as
reduced clearance by the kidney may contribute [253–255]. We and others showed Fgf23
expression in kidneys from PKD and diabetic nephropathy animal models [227, 240]. Our
data demonstrate that elevated plasma FGF23 levels in Pkd1 conditional KO mice par-
alleled renal Fgf23 expression as well as an increase in renal expression of typical bone
marker genes such as Runx2 and Dmp-1. Whether transformation of renal cells into the
osteogenic lineage promotes or underlies Fgf23 expression in kidney remains to be estab-
lished.
Renal inflammation and local hypoxia are common disease denominators in CKD [243–
247, 256, 257]. In PKD, hypoxia is present in tissue sourrounding cysts [243, 244, 256].
Hypoxia increases Fgf23 expression in UMR-106 rat osteosarcoma cells [139]. Further,
C-terminal but not intact plasma FGF23 was increased in rats housed under hypobaric
hypoxia conditions [139]. We cultured MC3T3-E1 cells, a mouse preosteoblast cell line as
well as primary mouse osteoblasts for 24 and 48 hours in 0.2% hypoxia and we did not
observe any stimulatory effect of hypoxia on Fgf23 expression. On the contrary, hypoxia
suppressed the stimulatory effect of 1,25(OH)2 vitamin D3 on Fgf23 mRNA expression.
PKD kidneys are also affected by inflammation [245, 257] as confirmed by the increased re-
nal Tnfα and Tgfβ expression NfκB subunit p65 phosphorylation in our model. Tnfα/NfκB
may signal to increase Nurr1 expression, an orphan nuclear receptor which is involved in
the Pth dependent regulation of Fgf23 expression in bone [133, 239]. We found that Nurr1
expression was upregulated in PKD kidneys and is predominantly localized in the cell nu-
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cleus whereas in wild type kidneys it is localized in the cytoplasm. Nuclear localization
of Nurr1 often but not exclusively overlapped with renal Fgf23 protein expression. This
finding suggests that Nurr1 may contribute to renal Fgf23 but other factors are likely to
be involved.
Ito et al. (2015) showed that inflammatory markers such as Tnfα, IL-1β, and LPS in-
creases Fgf23 mRNA expression in the IDG-SW3 mouse osteocyte cell line in a dose
and time dependent manner [147]. Similarly, we observed a Tnfα induced increase in
Fgf23 mRNA expression in primary mouse osteocytes which was comparable to the well
investigated effect of 1,25(OH)2 vitamin D3 on Fgf23 expression. However, Tnfα but
not 1,25(OH)2 vitamin D3 increased Nurr1 and Galnt3 expression in primary osteocytes.
This result suggests that Tnfα but not 1,25(OH)2 vitamin D3 may regulate Fgf23 expres-
sion in a Nurr1 dependent manner. In addition, Tnfα may also modulate Fgf23 protein
stability by regulating the expression of Galnt3. Galnt3 mediates the O-glycosylation of
Fgf23 which makes the protein more resistant against proteolytic degradation [102]. In
bone, C-terminal Dmp-1 binds with its acidic serine- and asparate-rich motif (ASARM)
to the membrane protein Phex and this interaction inhibits Fgf23 expression [125]. In
primary osteocytes, Phex expression was decreased by 1,25(OH)2 vitamin D3 whereas
Dmp-1 expression was strongly decreased by Tnfα and 1,25(OH)2 vitamin D3. Therefore
the upregulation of Fgf23 expression by Tnfα and 1,25(OH)2 vitamin D3 is paralleled
by the downregulation of its suppressors. The downregulation of Phex and Dmp-1 by
inflammatory markers was also observed in the IDG-SW3 cell line [147].
In patients with CKD, TNFα is increasing with ascending FGF23 quartiles and signifi-
cantly correlates with FGF23 levels independent of renal function and measures of min-
eral metabolism [142]. A similar observation was made in non CKD stroke patients where
markers of inflammation correlate with ascending FGF23 quartiles [143]. Furthermore dis-
eases characterized by inflammation such as inflammatory bowel disease or osteoarthritis
are linked to elevated serum FGF23 or increased FGF23 gene expression levels, respec-
tively [144, 145]. Inoculation of mice with LPS or bacteria leads to an increase in serum
Fgf23 levels [149]. In the diabetic nephropathy rat model, renal Fgf23 expression was
reduced with ramipril, an ACE inhibitor [227]. Ramipril lowers blood pressure but ad-
ditionally reduces inflammatory responses in patients with type 2 diabetes [258]. The
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link between Tnfα and Fgf23 is further supported by the finding that the neutralization of
Tnfα reduced renal Tnfα and Tgfβ expression in Pkd animals and concomitantly decreased
plasma Fgf23 levels in both PKD diseased and wild type animals. In PKD animals, the
decrease in plasma Fgf23 was more pronounced and accompanied by lower renal Fgf23 and
Nurr1 expression. These results strongly suggest that the inflammatory cytokine Tnfα
modulate Fgf23 expression.
In summary, we show that ectopic renal Fgf23 expression is triggered by the inflamma-
tory cytokine Tnfα and that Tnfα neutralization decreases elevated plasma Fgf23 levels
in PKD animals.
3.2.5 Methods
Animals
Pkd1 floxed/floxed (Pkd1fl/fl) tamoxifen inducible cre mice were kindly provided by Gre-
gory Germino [201, 202]. Cre recombinase expression is under the control of the β-actin
promoter which drives high levels of expression in most tissues [202]. Male and female
Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice were used. Cre recombinase activity was induced
at postnatal days 15, 17, and 19 by injecting pups with 100 µl tamoxifen (2.5mg/ml) in
corn oil causing slow onset disease [202]. Without further interventions, 24 hour urine was
collected from 6 and 12 weeks old animals (e.g. 4 or 10 weeks after induction, respectively)
which were thereafter sacrificed to collect plasma and organs. For Tnfα blockade, animals
were treated at the age of 12 weeks with a single i.p. injection of 0.5mg InVivoMAb anti-
Tnfα (Clone XT3.11, Lot4653-1/0413, BioXCell, USA) or InVivoMAb rat IgG1 (Clone
HRPN, Lot 5339/1014, BioXCell, USA) [259, 260]. Twenty-four hours after antibody ap-
plication, animals were sacrificed and plasma and organs were collected. All animal studies
were performed according to protocols approved by the legal authority (Veterinary Office
of the Canton of Zurich).
Plasma and urine analysis
Blood and 24 hours urine were collected from Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice
at 6 and 12 weeks after birth. Briefly, Pkd1fl/fl, cre mice were kept for three days in
metabolic cages (Tecniplast, Italy) whereas the last day was used for 24 hours urine col-
lection. Afterwards mice were anesthetized with isoflurane and blood was collected from
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the heart. Plasma and urine aliquots were rapidly frozen and stored at -80◦C until mea-
surement. Urine and plasma laboratory analyses were performed on a UniCel DxC 800
Synchron (Beckman Coulter, Switzerland) by the Zurich Integrative Rodent Physiology
(ZIRP) core facility.
The ratio of the maximum rate of tubular phosphate reabsorption to the glomerular fil-
tration rate (TmP/GFR) was calculated as follows:
TmP/GFR in mmol/L = PP − [UP × Pcrea/Ucrea]
where PP , UP , Pcrea , and Ucrea refer to the plasma and urinary concentration of phosphate
and creatinine, respectively [230]. The plasma concentration of intact FGF23 (Kainos
Laboratories, Japan or Immutopics International, USA), intact PTH (Immutopics In-
ternational, USA) and Tnfα (Life Technologies Europe, Switzerland) were measured by
enzyme-linked immunosorbent assays according to the manufacturers protocols.
Cell culture
All cell culture reagents were from Life Technologies Europe B.V. (Switzerland) unless
stated otherwise. Two to four month old Pkd1fl/fl, cre mice (4-6 per experiment) were
sacrificed with carbon dioxide. Tibias and femurs from the hindlegs were harvested. The
epiphyses were cut and bones were flashed with Hank’s Balanced Salt Solution (HBSS)
containing 1% penicillin streptomycin (Pen Strep) to remove the bone marrow. Bones
were cut into small pieces of 1-2 mm2. Bone cell extraction was performed according
established protocols [249, 250]. Briefly, small bone pieces were repeatedly digested with
either a solution containing 2 mg/ml collagenase type II, 0.05% (w/v) soyabean trypsin
inhibitor (Sigma-Aldrich, Switzerland), 20 mM HEPES, 1% Pen Strep in HBSS or 10 nM
EDTA, 1% fetal bovin serum (FBS), 1% Pen Strep in phosphate buffered saline (PBS)
for 25min at 37circC. Cells from digestion steps 6-9 or cells and bone pieces from di-
gestion step >9 were cultured for 2 weeks in an osteogenic medium (minimal essential
medium α (memα) containing 10% FBS, 1% Pen Strep, 50 µg/ml 2-phospho-L-ascorbic
acid trisodium salt (Sigma-Aldrich, Switzerland), and 1mM β-glycerophosphate (Sigma-
Aldrich, Switzerland)). After 2 weeks, cells were supplemented for 24 hours with either
10 nM 1,25 (OH)2 vitamin D3 (CaymanChemical, USA) or 10 ng/ml mouse Tnfα (R&D
Systems, USA) and total mRNA was extracted.
73
MC3T3-E1 subclone 4 preostoblast cells (CRL-2593, Lot 59899932, ATCC France) pas-
sage 17/4 were expanded for 4-5 days with memα medium supplemented with 10% FBS
and 1% PenStrep. After reaching 80-90% confluence, MC3T3-E1 cells were trypsinized
and plated in collagen coated 6 well plates (80’000 cells/well). Medium was changed to
osteogenic differentiation medium (memα supplemented with 10% FBS, 1% PenStrep, 50
µg/ml 2-Phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich, Switzerland), and 1 mM
beta glycerophosphate (Sigma-Aldrich, Switzerland)). After 2 weeks differentiation along
the osteogenic lineage cells were supplemented for 24 or 48 hours with either 10 nM 1,25
(OH)2 vitamin D3 (CaymanChemical, USA) or an equal amount of EtOH and incubated
for 24 or 48 hours under hypoxic (0.2% O2) or normoxic conditions.
RNA extraction and RT-PCR
Organs were harvested at week 6 and 12 and were rapidly frozen in liquid nitrogen. Tissues
were homogenized using either a Precellys homogenizer or a liquid nitrogen cooled mortar
and pestle (bone). Total mRNA from bone as well as from cultured cells was extracted
with TRIzol (Life Technologies Europe B.V., Switzerland) followed by purification with
RNeasy Mini Kit (Qiagen, Switzerland) according to the manufacturers protocol. Total
mRNA from kidney was extracted with RNeasy Mini Kit (Qiagen, Switzerland) according
to the manufacturers protocol. DNAse digestion was performed using the RNase-free
DNAase Set (Qiagen, Switzerland). Total RNA extractions were analyzed for quality,
purity, and concentration using the NanoDrop ND-1000 spectrophotometer (Wilmington,
Germany). RNA samples were diluted to a final concentration of 100 ng/µl and cDNA
was prepared using the TaqMan Reverse Transcriptase Reagent Kit (Applied Biosystems,
Roche, Foster City, CA). In brief, in a reaction volume of 40 µl, 300 ng of RNA was used as
template and mixed with the following final concentrations of RT buffer (1x): MgCl2 (5.5
mmol/l), random hexamers (2.5 µmol/l), dNTP mix (500 µmol/l each), RNase inhibitor
(0.4 U/µl), multiscribe reverse transcriptase (1.25 U/µl), and RNAse-free water. Reverse
transcription was performed with thermocycling conditions set at 25◦C for 10 min, 48◦C
for 30 min, and 95◦C for 5 min on a thermocycler (Biometra, Germany). Quantitative
realtime PCR (RT-PCR) was performed on the ABI PRISM 7700 Sequence Detection
System (Applied Biosystems). Primers for genes of interest were designed using Primer
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3 software [242, 261]. Primers were chosen to span intron - exon boundaries to exclude
genomic DNA contamination. The specificity of all primers was tested and always resulted
in a single product of the expected size (data not shown). Probes were labeled with the
reporter dye FAM at the 5’-end and the quencher dye TAMRA at the 3’-end (Microsynth,
Switzerland). RT-PCR reactions were performed using the KAPA PROBE FAST RT-PCR
Kit (KappaBiosystems, USA).
Protein extraction and Western blot analysis
Organs were rapidly frozen in liquid nitrogen. Tissues were homogenized in a homoge-
nization buffer containing 0.27 M sucrose, 2 mM EDTA (pH8), 0.5% NP-40, 60 mM KCl,
15 mM NaCl, 15 mM HEPES (pH 7.5) (all Sigma-Aldrich, Switzerland) and cOmplete
protease inhibitor cocktail (Roche, Switzerland) using a Precellys homogenizer. Nuclear
proteins were separated by a sucrose cushion and resuspended in a nuclei extraction buffer
containing 20 mM HEPES (pH 7.5), 400 mM NaCl, 1 mM EDTA (pH 8), 1 mM DTT and 1
mM PMSF (all Sigma-Aldrich, Switzerland). After measurement of protein concentration
(Bio-Rad, Hercules, CA, USA), 60 µg of nuclear proteins were solubilized in loading buffer
containing DTT and separated on a 10% polyacrylamide gel. For immunoblotting, proteins
were transferred electrophoretically to polyvinylidene fluoride membranes (Immobilon-
P, Millipore, Bedford, MA, USA). After blocking with 5% milk powder in Tris-buffered
saline/0.1% Tween-20 or 5% bovine serum albumin (BSA) in Tris-buffered saline/0.1%
Tween-20 for 60 min, blots were incubated with the primary antibodies: mouse mono-
clonal anti-Phospho-NFκB p65 (Ser536)(7F1) (Cell Signaling Technology, USA; 1:1000)
or rabbit monoclonal NFκB p65 (D14E12) (Cell Signaling Technology, USA; 1:1000) ei-
ther for 2 h at room temperature or overnight at 4◦C. Membranes were then incubated
for 1 h at room temperature with secondary goat anti-rabbit or donkey anti-mouse an-
tibodies (1:5000) linked to alkaline phosphatase (Promega, USA) or HRP (Amersham,
MA, USA or R&D Systems, USA). The protein signal was detected with the appropriate
substrates using the DIANA III-chemiluminescence detection system (Raytest, Strauben-
hardt, Germany). All images were analyzed using the software Advanced Image Data
Analyser AIDA, Raytest to calculate the ratio between phosphorylated protein to total
protein.
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Immunofluorescence staining
Mouse kidneys were perfused in situ through the left heart ventricle with a fixative solution
containing 3% paraformaldehyde in phosphate buffered saline (PBS). Kidneys were em-
bedded in TissueTec and frozen in liquid nitrogen. Five µm cryosections were cut. Slides
were rehydreated with PBS, treated for 5 min with 0.5% SDS in PBS followed by 10 min
treatment with 0.5% Triton-X-100 in PBS (Sigma-Aldrich, Switzerland). Unspecific sites
were blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at room temperature.
Primary antibodies were diluted in 1% BSA in PBS (rat anti-FGF23 clone #283507 (R&D
Systems, USA) 1:1000; rabbit anti-Nurr1 N-20 sc-991 (Santa-Cruz, USA) 1:200) and kid-
ney sections were incubated with the primary antibody overnight at 4◦C. After washing
with PBS, sections were incubated with the corresponding secondary antibody (1:500)
(anti-rabbit DyLight 594 (Jackson ImmunoResearch, Europe), anti-rat NL493 (R&D Sys-
tems, USA)), and DAPI (Life Technologies Europe B.V., Switzerland, 1:1000) for 1 h at
room temperature. Slides were washed twice with PBS before they were mounted with
Dako glycergel mounting medium (Dako, Switzerland). Sections were visualized on a Leica
DM 5500B fluorescence microscope and images processed with ImageJ.
Statistical analysis
Statistics were performed using unpaired Student‘s t-test or ANOVA (GraphPad Prism
version 5.0, GraphPad, San Diego, CA). Data are provided as mean ± SD. P < 0.05 was
considered significant.
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3.2.8 Supplementary Data
Supplementary Figures
Figure 3.24: Nurr1 staining in kidneys from Pkd1fl/fl, cre+ mice. Immunofluorescense
staining for FGF23 (green), Nurr1 (red), and DAPI (blue, cell nuclei) merged and single channels:
(a-d) kidneys from 12 weeks old Pkd1fl/fl, cre+ mice, (e) kidneys from 12 weeks old Pkd1fl/fl,
cre+ mice incubated with secondary antibodies alone. Original magnification (a, c, e) 400x (scale
bar 50 µm) and (b, d) 1000x (scale bar 20 µm).
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Figure 3.25: Nurr1 staining in kidneys from Pkd1fl/fl, cre- mice. Immunofluorescense
staining for FGF23 (green), Nurr1 (red), and DAPI (blue, cell nuclei) merged and single channels:
(a-d) kidneys from 12 weeks old Pkd1fl/fl, cre- mice, (e) kidney from 12 weeks old Pkd1fl/fl, cre+
mice incubated with secondary antibodies alone. Original magnification (a, c) 400x (scale bar 50
µm) and (b, d) 1000x (scale bar 20 µm).
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Figure 3.26: 1,25 (OH)2 vitamin D3 dependent Fgf23 expression in MC3T3-E1 cells
under normoxic and hypoxic conditions. MC3T3-E1 cells were differentiated for two weeks
along the osteogenic lineage. Subsequently, cells were supplemented for 24 or 48 hours with 10nM
1,25 (OH)2 vitamin D3 and incubated in hypoxic (0.2% oxygen) or normoxic conditions. Relative
Fgf23 (a), Ca9 (b), Phd2 (c) mRNA expression. Mean ± SD; n=3; * p<0.05
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Table 3.2: Primer and probe sequences used for RT-PCR
Gene Type Sequence
Mouse Pkd1 Fwd 5’-GGCCAACCTCTCCTCAGTATC-3’
Rev 5’-GAAGGGTACTGCTGCCACA-3’
Probe 5’-CTGTGGTGAGGAATATGTCGCCTGC-3’
Mouse Fgf23 Fwd 5’-TCGAAGGTTCCTTTGTATGGAT-3’
Rev 5’-AGTGATGCTTCTGCGACAAGT-3’
Probe 5’-TTTTTGGATCGCTTCACT-3’
Mouse Fgf23 Fwd 5’-GTATGGATCTCCACGGCAAC-3’
Rev 5’ AGTGATGCTTCTGCGACAAGT-3’
Probe 5’-TTTTTGGATCGCTTCACTTCAGCCC-3’
Mouse Galnt3 Fwd 5’-GAGAAAGAGCGAGGGGAAAC-3’
Rev 5’-GTGGACCATGCTTCATTGTG-3’
Probe 5’-ACACCCGACCACCTGAATGTATTGAAC-3’
Mouse Phex Fwd 5’-GCTGCCAGAGAACAAGTGC-3’
Rev 5’-TCCTCAGCTATGCCAGGAAG-3’
Probe 5’-CAGTCCTCCACAATTTAGGGTCAATGGTG-3’
Mouse Bmp-1 Fwd 5’-ACAGCAAACAGCCCGAAG-3’
Rev 5’-TCCAATCACAAACGGGATG-3’
Probe 5’-CCATCCATCAAAGCTGCAGGAAACTC-3’
Mouse Dmp-1 Fwd 5’-TCTCCCAGTTGCCAGATACC-3’
Rev 5’-TCTCCAGATTCACTGCTGTCC-3’
Probe 5’-CTCTGAAGAGAGGACGGGTGATTTGG-3’
Mouse Runx2 Fwd 5’-CCCTGAACTCTGCACCAAGT-3’
Rev 5’-AGTGGATGGATGGGGATGT-3’
Probe 5’-TCAGATTACAGATCCCAGGCAGGCA-3’
Mouse Nurr1 Fwd 5’-CATCGACATTTCTGCCTTCTC-3’
Rev 5’-CTTCCACTCTCTTGGGTTCCT-3’
Probe 5’-TGCCCTGGCTATGGTCACAGAGAGA-3’
Mouse Tnfα Fwd 5’-CAGACCCTCACACTCAGATCATCT-3’
Rev 5’-CCTCCACTTGGTGGTTTGCT-3’
Probe 5’-ATTCGAGTGACAAGCCTGTAGCCCACGT-3’
Mouse Tgfβ Fwd 5’-AGAGGTCACCCGCGTGCTA-3’
Rev 5’-GCTTCCCGAATGTCTGACGTA-3’
Probe 5’-ACCGCAACAACGCCATCTATGAGAAAACC-3’
Mouse Ca9 Fwd 5’-GCACCTCAGTACTGCTTTCTCC-3’
Rev 5’-TTCCTCCGAGATTTCTTCCA-3’
Probe 5’-CCTTTCTGCAGGAGAGCCCAGAAGA-3’
Mouse Phd2 Fwd 5’-TGGGCAACTACAGGATAAACG-3’
Rev 5’-TGTCACGCATCTTCCATCTC-3’
Probe 5’-CGAAAGCCATGGTTGCTTGTTACCC-3’
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Chapter 4
Discussion
Phosphate is needed for various biological processes such as energy production, cell signal-
ing, mineralization of the endoskeleton as well as membrane and protein synthesis [1–6].
To fulfill its biological actions, serum phosphate levels have to be kept in a narrow range to
prevent the body from adverse events due to deficiency or excess. Fgf23, Pth, 1,25(OH)2
vitamin D3, and soluble Klotho build a tight endocrine network with multiple negative
feedback loops to control serum phosphate levels by regulating its intestinal absorption,
renal excretion and bone turnover (Figure 1.3) [18–20, 46]. In this context the hormonal
regulation of phosphate reabsorption by the kidney plays a key role in the maintenance of
serum phosphate levels. Both, Fgf23 and Pth lower serum phosphate concentrations by de-
creasing the abundance of sodium phosphate co-transporters NaPi-IIa and NaPi-IIc in the
brush border membrane of proximal tubules in the kidney [41, 44, 49, 83]. 1,25(OH)2 vita-
min D3 increases Fgf23 expression in bone and decreases Pth expression in the parathyroid
gland both in a VDR dependent manner [58, 63, 77, 128]. In the intestine, 1,25(OH)2 vita-
min D3 stimulates dietary phosphate reabsorption [47]. This leads to an overall increase in
serum phosphate levels by 1,25(OH)2 vitamin D3. In return, Fgf23 inhibits the synthesis
of 1,25(OH)2 vitamin D3 in the kidney by downregulation of Cyp27b1 and promotes the
degradation of 1,25(OH)2 vitamin D3 by upregulation of Cyp24a1 [77, 79]. Pth stimulates
1,25(OH)2 vitamin D3 production independent of serum Fgf23 levels and increases Fgf23
expression in bone [51, 52, 129]. In a negative feedback loop, Fgf23 inhibits Pth expression
and secretion in the parathyroid gland [91]. The function of soluble Klotho is not yet com-
pletely understood. On one hand administration of anti-Klotho antibodies increases Fgf23
levels suggesting that Fgf23 expression is suppressed by Klotho and on the other hand in
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vivo overexpression of circulating Klotho leads to an increase in Fgf23 expression in bone
[69, 141]. Taken all together, Fgf23 and Pth lower serum phosphate concentrations while
1,25(OH)2 vitamin D3 is doing the opposite. Thereby these hormones regulate each other
in multiple negative feedback loops and imbalance of the hormonal network due to disease
or congenital disorders leads to severe disturbances of phosphate homeostasis. Exactly
this can be observed in CKD where the decrease of renal function is entailed by step-
wise changes in mineral homeostasis (see Figure 1.7) [156, 157]. The changes of mineral
homeostasis in CKD start with a gradual decline of plasma and urine concentrations of
soluble Klotho [46, 158, 159]. Subsequently, FGF23 plasma levels increase in CKD stage
G2 to G3a which suppress in the kidney 1,25(OH)2 vitamin D3 synthesis and increase its
degradation [157]. The decrease in 1,25(OH)2 vitamin D3 levels and resistance to FGF23
initiate the pathogenesis of secondary hyperparathyroidism [156, 157]. Plasma PTH levels
increase in CKD stage G3b to G4 and therefore occurs later in the course of CKD com-
pared to the rise in plasma FGF23 [157]. Serum phosphate decreases in an initial phase
in consequence of high FGF23 levels [157]. In a second phase when eGFR drops below
59.1ml/min per 1.73 m2 phosphate levels gradually increase and patients with advanced
CKD suffer from hyperphosphatemia [156, 157]. Both, elevated FGF23 and phosphate
levels contribute to the higher mortality risk in ESRD [155, 166].
ADPKD is a monogenetic disorder which is characterized by bilateral kidney enlargement
where functional renal tissue is progressively replaced by growing cysts [171, 177]. ADPKD
is a cause for CKD and the progression of the disease leads to ESRD [151]. Genetic testing
and imaging methods allow ADPKD diagnosis before a detectable decline in renal function
occurs for which reason ADPKD is a useful model to study the entire evolution of CKD
and the concomitant changes in mineral homeostasis [189]. Pavik et al. (2011) found that
ADPKD patients with a nearly preserved renal function (CKD stage G1 and G2) have 4-
fold increased FGF23 levels compared to non-diabetic patients and patients with diabetes
mellitus type 2 and a similar CKD stage [184]. At the same time, plasma 1,25(OH)2 vita-
min D3 and PTH levels were normal in all CKD patients [184]. Within the ADPKD study
group, only those with normal soluble Klotho levels showed a mild decrease in plasma
phosphate concentration whereas the majority of ADPKD patients had low serum Klotho
levels [184, 185]. Administration of anti-Klotho antibodies in mice leads to an increase
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in plasma Fgf23 levels [69]. In a translational approach, the reduction of soluble Klotho
would explain the early increase in serum FGF23 levels in ADPKD patients. However, the
early rise in plasma FGF23 levels is a specific manifestation for ADPKD and cannot be
explained by decrease in renal function as this patients have a preserved eGFR [184]. The
goal of the first study was to examine the role of high FGF23 in ADPKD rodent models
such as Han:SPRD rats and Pkd1 conditional KO mice and to analyze the mechanisms
which may contribute to the early and excessive elevation of FGF23 in ADPKD.
4.1 PKD animal models
The Han:SPRD cy/+ rat is a well-established PKD animal model with a spontaneous mu-
tation in the Pkdr1 gene which encodes the SamCystein protein [216, 217]. Homozygous
Han:SPRD cy/cy rats have a rapid cyst development and die from renal failure within a
month after birth [218]. Heterozygous Han:SPRD cy/+ rats have little tubular changes
after 4 weeks thereafter cyst development progresses so that after 8 weeks significant cyst
formation can be observed [218]. Most of the cysts can be localized to proximal tubules
in the inner cortex [218]. Despite the cyst growth heterozygous animals survive more
than a year [218]. The Han:SPRD cy/+ rat model has been widely used for examining
mechanisms and therapies for ADPKD [220–223]. The aim of this study was to investigate
Fgf23 metabolism at an early time point of the disease and therefore we analyzed animals
between 2 and 8 weeks of age.
The Pkd1 KO mouse model is the orthologue model for human ADPKD disease. Un-
fortunately, homozygous Pkd1 KO animals develop edema as well as renal cysts in an
embryonic state and die already in utero whereas heterozygous Pkd1 mice rarely develop
cystic kidneys before 6 months [198–200]. To bypass these problems Piontek et al. (2004)
developed the Pkd1 conditional KO mouse model [201]. In this mouse model, Pkd1 exons
2 to 4 are flanked by unidirectional loxP sites which can be excised by Cre recombinase
[201]. This leads to a complete Pkd1 null allele and renal cyst formation [201]. In this
study we used the Pkd1fl/fl mouse carrying a tamoxifen inducible Cre recombinase driven
by the beta-actin promoter. The time point of Pkd1 inactivation defines the kinetics of
kidney cyst formation and an induction until day 12 post partum results in severe cystic
disease within 3 weeks whereas an induction after day 14 results in a late onset cystic dis-
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ease where cysts appear after 3 month and become severe after 6 month [202, 203]. Since
we wanted to investigate the sequential hormonal changes observed in CKD, we decided
for a late induction of Cre recombinase at postnatal days 15, 17 and 19. With our protocol
we observed slightly different cyst growth kinetics as reported by Piontek et al. (2007)
[202]. Pkd1fl/fl, cre+ animals had no considerable tubular changes after 6 weeks and the
two kidney per body weight ratio was similar to wild type animals. Within the next four
weeks Pkd1fl/fl, cre+ animals suffered from severe cyst growth and at week 10 the two
kidney per body weight ratio was twice as high as at week 6. At this time point kidney
cysts could be easily seen by eye. After 12 weeks, kidneys of Pkd1fl/fl, cre+ animals were
massively cystic and the two kidney per body weight ratio doubled once more compared to
animals at 10 weeks. We used the same tamoxifen concentration as Piontek et al. (2007)
but injected it three times directly to the pups whereas Piontek et al. (2007) did it once to
the nursing mother. Therefore we suggest that cyst growth kinetics depends not only on
the developmental switch at day 12 but also from the overall tamoxifen dose given to the
PKD animals. Nevertheless, regardless of the protocol, Cre recombinase induction after
day 14 results in a slow disease progression model which is ideal to study the sequential
hormonal changes observed in CKD.
4.2 FGF23 metabolism in PKD animals
We observed a 10-fold increase in plasma Fgf23 levels in Han:SPRD cy/+ rats at week 4
which was accompanied by a 2-fold increase in plasma Pth and normal 1,25(OH)2 vitamin
D3 levels. The progressive cyst growth leads to a decline in renal function which starts
in Han:SPRD cy/+ rats at week 8 [218]. This was consistent with our observation that
plasma creatinine and urea concentrations were similar after 4 weeks but started to in-
crease after 6 weeks and further rose at 8 weeks. This implies that the increase in plasma
Fgf23 levels occured at a time point when renal function was still near normal. Simi-
larly, in Pkd1 conditional KO animals we observed elevated plasma Fgf23 and unchanged
Pth levels whereas creatinine clearance was normal. Hence, our PKD animal models ac-
curately reproduces the observed increase of FGF23 levels in the early disease course of
human ADPKD and allows to approach the underlying mechanisms in more detail.
The physiological function of FGF23 is to lower phosphate levels by decreasing the abun-
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dance of sodium phosphate co-transporters at the brush border membrane of proximal
tubules in the kidney as well as to inhibit 1,25(OH)2 vitamin D3 synthesis [61, 65, 77–79].
Elevated FGF23 levels in human caused by gain of function mutations in FGF23 or ex-
cessive secretion of FGF23 in the context of tumor-induced osteomalcia are accompanied
by hypophosphatemia, urinary phosphate wasting and low 1,25(OH)2 vitamin D3 levels
[61, 100]. Administration of single dose recombinant Fgf23 in mice leads to a decrease
in serum phosphate and 1,25(OH)2 vitamin D3 levels and to an increase in the fractional
excretion of phosphate [64, 77]. Despite the high plasma Fgf23 levels in Han:SPRD cy/+
rats and Pkd1 conditional KO mice, plasma phosphate levels as well as TmP/GFR were
normal over the entire study period. In Han:SPRD cy/+ rats, expression and activity of
sodium phosphate co-transporters was normal. The majority of cysts in Han:SPRD cy/+
rats originate from the proximal tubule and display varying degrees of proximal tubular
brush border membrane degradation and transition zones from intact brush border mem-
brane to dedifferentiated epithelial cells [218]. Cysts with intact brush border membrane
had normal NaPi-IIa protein expression whereas in the same cysts in dedifferentiated ep-
ithelial cells NaPi-IIa protein was missing. Furthermore, Han:SPRD cy/+ rats had no
change in vitamin D3 metabolism. There were neither changes in 1,25(OH)2 vitamin D3
plasma levels nor in the expression of Cyp27b1 and Cyp24a1. These findings went along
with the observation in human ADPKD patients where against expectations, only a small
fraction of ADPKD patients with normal renal function and elevated serum FGF23 levels
was affected by a renal leak of phosphate and mild hypophosphatemia whereas most of
them had a normal renal phosphate handling [184]. Ascending FGF23 quartiles are associ-
ated with left ventricular hypertrophy in human CKD patients [225]. In mice, repeatedly
intravenous injections of Fgf23 increase the heart weight per tibia length ratio and leads
to a thickening of the left ventricular heart wall [225]. The heart does not express Klotho,
the obligate co-ligand for Fgf23 signaling therefore Fgf23 exerts its effect in a calcineurin
dependent pathway [225]. Despite high Fgf23 levels non of our PKD animal models had a
change in heart weight per tibia length ratio suggesting either that Fgf23 requires longer
time periods, stronger elevation or that the heart is resistant to high Fgf23 levels. Taken
together, PKD animals as well as human ADPKD patients with normal kidney function
show resistance against highly elevated FGF23 levels. However, the temporal sequence of
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rising FGF23 in PKD and the mechanisms underlying resistance to the biological actions
of FGF23 remained at this point unclear.
To further investigate the underlying mechanism of Fgf23 resistance in PKD animals we
analyzed the Fgf23 signaling cascade in the kidney. Fgf23 binds in the kidney to the Fgfr-
Klotho receptor complex which leads to the dimerization and cross-phosphorylation of Fgfr
tyrosine kinase domains and activates among others the downstream signaling molecule
FRS2α (Figure 1.5) [69]. Fgf23 binds to the Fgfr isoforms Fgfr1c, Fgfr3c, and Fgfr4 but
it has been shown that in the kidney Fgfr1 displays a key function in mediating Fgf23 de-
pendent phosphaturia [84–87]. Fgf23 transgenic mice have no changes in Fgfr expression
levels in the kidney but rather resist increased Fgf23 signaling by the downregulation of
Klotho expression [226]. We found that elevated plasma Fgf23 levels in Han:SPRD cy/+
rats had no effect on Fgfr1 expression in the kidney. We detected lower renal Klotho
gene expression levels in PKD animals but at the protein level Klotho abundance was
unchanged. In Han:SPRD cy/+ rat kidney, phosphorylation of the downstream molecule
FRS2α was increased suggesting that Fgf23 signaling can be activated but may be blocked
further downstream.
Han:SPRD cy/+ rats had higher plasma Pth levels than control rats which is in contrast
to ADPKD patients with normal renal function [184]. This divergence is also observed
in other CKD rat models where Fgf23 and Pth rise at the same time point in contrast
to human CKD patients where FGF23 rises before PTH in the course of CKD [157, 161].
CKD rat models have a relative fast disease progression which reduces the temporal reso-
lution of hormonal changes in the course of CKD. Therefore shorter measurement intervals
or animals with slower disease progression may overcome this gap. Fgf23 decreases Pth
expression and secretion by the parathyroid gland in a Klotho dependent as well as in
calcineurin dependent pathway [91, 93, 97]. Loss of Klotho might be partially involved in
induction of Fgf23 resistances in the parathyroid gland and the concomitant increase in
Pth levels.
We further addressed the question what causes elevated plasma Fgf23 levels and took
either increased expression or decreased degradation into consideration. Screening for
Fgf23 expression in bone, spleen, kidney, heart, and liver revealed bone, as the major
source of Fgf23 expression whereas small amounts were expressed in spleen [61, 62, 65].
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Unexpectedly we detected Fgf23 mRNA and protein expression in the kidneys of PKD
animals more precisely in the cells lining the cysts. In the mouse and rat PKD model,
Fgf23 expression was increased in PKD kidneys whereas expression in bone and spleen was
similar to control animals suggesting that the kidney may contribute to elevated plasma
Fgf23 levels. Similarly, renal Fgf23 expression was reported in a diabetic nephropathy
rat model [227]. Fam20c protein phosphorylates Fgf23 which inhibits O-glycosylation and
leads to the degradation and inactivation of Fgf23 [108, 114]. We observed neither in bone
nor in kidneys of Han:SPRD cy/+ rats a change in Fam20c expression suggesting that
local Fgf23 degradation is unchanged. Interestingly, Dmp-1, another bone marker protein,
was elevated in the kidneys of Han:SPRD cy/+ rats but how this correlates with renal
Fgf23 expression as well as the mechanism causing ectopic renal Fgf23 expression is so far
unknown.
4.3 Regulation of renal Fgf23 expression in PKD
In the second project we examined the causes of renal Fgf23 expression in the Pkd1 con-
ditional KO mouse model. To identify possible triggers for renal Fgf23 expression we
compared our PKD animals with the diabetic nephropathy rat model of Zanchi et al.
(2013) which displayed as well renal Fgf23 expression [227]. We hypothesized that hy-
poxia and inflammation are overlapping conditions in the two CKD animal models and
investigated the effect of these two factors on Fgf23 expression in bone cell culture models
as well as in kidneys of Pkd1 conditional KO mice.
Iron deficiency causes anemia and leads in vivo and in vitro to an increase in Fgf23 gene
expression in bone [136]. Furthermore, hypoxia directly upregulates Fgf23 expression in
UMR-106 rat osteosarcoma cells [139]. Iron deficiency induced Fgf23 expression in UMR-
106 cells is blocked by MAPK inhibitors and increased by Hif1α activators [136]. To the
contrary, we did not see any effect on Fgf23 expression in primary mouse osteoblasts cul-
tured in 0.2% hypoxia. Furthermore hypoxia repressed 1,25(OH)2 vitamin D3 induced
Fgf23 expression in MC3T3-E1 mouse preosteoblast cells. Despite the negative results we
undertook another effort to investigate whether Fgf23 may be a direct or indirect Hif1α
or Hif2α target gene. Loss of Von Hippel-Lindau (Vhl) protein prevents Hif from hydrox-
ylation and degradation in the cytoplasma which leads to the translocation of Hif to the
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nucleus where it activates hypoxia sensitive genes [252]. Vhl conditional KO mice have
increased expression of Hif target genes due to impaired degradation of Hif [262]. We
quantified Fgf23 expression in kidneys of Vhl KO animals as well as in primary kidney
cells lacking Vhl but neither the kidneys of Vhl KO animals nor the cells lacking Vhl
expressed Fgf23. Thus, hypoxia alone is not sufficient to trigger Fgf23 expression in PKD
animals.
In CKD patients, IL-6 and TNFα correlate with FGF23 levels independent of renal func-
tion and measures of mineral metabolism [142]. Recently, it has been shown that inflam-
matory cytokines such as Tnfα, Il-1β, and LPS directly stimulate Fgf23 expression in the
IDG-SW3 osteocyte cell line as well as in ex vivo cultured human trabecular bone [147].
We found that Tnfα increases Fgf23 expression in primary mouse osteocytes similar as
1,25(OH)2 vitamin D3. Tnfα/NfκB signaling increases the expression of the nuclear re-
ceptor and early response gene Nurr1 which is involved in the Pth dependent regulation
of Fgf23 expression in bone [133, 239]. In response to Tnfα but not 1,25(OH)2 vitamin D3
primary osteocytes upregulated Nurr1 expression suggesting that Tnfα dependent upreg-
ulation of Fgf23 is indirect via Nurr1. O-glycosylation of FGF23 by GALNT3 is a critical
step in FGF23 processing and prevents premature degradation of Fgf23 [102]. Tnfα stim-
ulated Galnt3 expression in primary mouse osteocytes and might thereby enhance the
stability of Fgf23 protein. Both, Dmp-1 KO mouse as well as the Hyp mouse model suffer
from low 1,25(OH)2 vitamin D3 levels and hypophosphatemic rickets [79, 115–118]. Mar-
tin et al (2012) demonstrated that the interaction of C-terminal Dmp-1 with the ASARM
sequence of the membrane protein Phex locally represses Fgf23 expression in bone [125].
In the primary osteocyte cells, Dmp-1 was repressed by Tnfα and 1,25(OH)2 vitamin D3
whereas Phex expression was only repressed by 1,25(OH)2 vitamin D3.
The finding that the inflammatory cytokines Tnfα impacts Fgf23 gene expression as well
as the expression of Fgf23 regulatory genes allowed us to go back to our initial hypothesis
that inflammation may regulate ectopic Fgf23 expression in the kidneys of Pkd1 condi-
tional KO animals. At week 6, Pkd1fl/fl, cre+ mice were similar to the control mice
and had a normal two kidney per body weight ratio, plasma Fgf23 and Pth levels as
well as normal phosphate handling and intact renal function. At week 12, the two kid-
ney per body weight ratio was drastically increased in Pkd1fl/fl, cre+ mice and they
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displayed increased plasma Fgf23 levels and decreased Pth levels. Further they had a
reduced phosphate reabsorption whereas renal function was slightly decreased as apparent
from increased BUN but unchanged creatinine clearance. Tamoxifen administration led
to an appropriate downregulation of Pkd1 gene expression and the remaining expression
amounted 19% and 74% after 6 and 12 weeks, respectively. In human ADPKD patients,
high PKD1 expression of the intact allele is persistent in the majority of cysts and may
explain the high remaining expression levels in the PKD animals at week 12 [241]. We
confirmed the expression of the bone marker genes Fgf23, Runx-2 and Dmp-1 in the cystic
kidneys of 12 weeks old Pkd1fl/fl, cre+ animals whereas the expression of these genes were
unchanged in bone.
TNFα is secreted into the cyst fluid of human ADPKD patients and contributes in het-
erozygous Pkd2 KO animals to cyst formation and cyst growth [257]. Tnfα induces its
own transcription by a NfκB dependent pathway and has a prosurvival effect on embryonic
epithelial cells of Pkd1null mice [263]. We proved the presence of inflammatory markers
in PKD kidneys and found that Tnfα and Tgfβ expression as well as phosphorylation of
the NfκB subunit p65 is increased in PKD animals at week 12. NfκB binds upon Tnfα
activation to the promoter region of the orphan nuclear receptor Nurr1 [239]. Nurr1 is an
early response gene and stimulates in bone Fgf23 expression [133]. In PKD animals Nurr1
expression is strongly increased at week 12. Furthermore Nurr1 localization switched from
the cytoplasm into the nucleus in PKD animals whereas it remained in the cytoplasm in
wild type animals. Nuclear localization of Nurr1 is frequently but not exclusively co-
localized with Fgf23 expression suggesting that further factors are necessary to induce
FGF23 expression in PKD kidneys.
Osteoarthritis and inflammatory bowel disease (IBD) are both diseases characterized by
inflammation and elevated TNFα levels and are linked to abnormal FGF23 expression
[144, 145]. Chondrocytes derived from osteoarthritis patients display elevated FGF23
gene expression [144]. In children with IBD plasma FGF23 levels are increased in the
acute phase whereas they are normal in the remission phase [145]. The increase in plasma
FGF23 levels in the acute phase can be suppressed by treatment with the anti-TNFα
antibody infliximab [145]. Renal Fgf23 expression in a diabetic nephropathy rat model
was reduced after treatment with ramipril, an ACE inhibitor [227]. Beside blood pres-
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sure reduction, ramipril is known to lower inflammation markers in patients with type
2 diabetes due to decreased production of the proinflammatory mediator angiotensin II
[258, 264]. Angiotensin II increases Tnfα expression and reduces Klotho expression in the
kidney which might explain the effect of ramipril in the diabetic nephropathy rat model
[163, 227, 264, 265]. We tested the effect of Tnfα blockade in our PKD model and found
that a single injection of anti-Tnfα antibodies lowers plasma Fgf23 levels in Pkd1 con-
ditional KO animals independent of the genotype and decreases the expression of Tnfα
and Tgfβ in the kidneys of Pkd1fl/fl, cre+ animals. The administration of anti-Tnfα
antibodies tended to result in lower Fgf23 and Nurr1 expression in the kidneys of PKD
animals. Further evidence that Fgf23 is involved in inflammatory processes comes from
the observation that serum Fgf23 levels of mice inoculated with LPS, E. coli, or S. au-
reus were increased [149]. Under this conditions, Fgf23 expression in spleen turned out
to be elevated [149]. Within the spleen mainly the bone marrow derived dendritic cells
and to a lower extent macrophages were responsible for increased Fgf23 expression levels
[149]. Our results strongly suggest that Tnfα modulates Fgf23 expression and secretion
in polycystic kidney disease but the exact physiological function of Tnfα induced Fgf23
expression within the inflammatory response has to be elucidated in future.
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Chapter 5
Summary
This project originated from the clinical observation that ADPKD patients with normal
renal function have elevated plasma FGF23 levels. The aim of this project was to examine
the role of high Fgf23 in PKD rodent models such as Han:SPRD cy/+ rats and Pkd1 con-
ditional KO mice. We found that plasma Fgf23 levels were increased in Han:SPRD cy/+
rats at a time point when renal function was apparently normal. Therefore Han:SPRD
cy/+ rats accurately reproduced the observed increase of FGF23 levels in the early dis-
ease course of human ADPKD and allow to approach the underlying mechanism in more
detail. Despite the high Fgf23 levels, phosphate and calcium handling as well as vitamin
D3 metabolism were unchanged, indicating resistance to Fgf23. We analyzed the early
mediators of Fgf23 signaling in the kidney and found no differences in Fgfr and Klotho
expression and FRS2α phosphorylation was even enhanced in Han:SPRD cy/+ rats. We
evaluated the source of Fgf23 and found that Fgf23 expression in kidney but not in bone
was increased in Han:SPRD cy/+ rats and Pkd1fl/fl, cre+ mice. We detected Fgf23 pro-
tein expression in cells lining renal cysts. This raised the question how the expression and
secretion of Fgf23 in bone and the de novo Fgf23 expression in kidney are triggered in
PKD. We tested the hypothesis that local hypoxia or inflammation triggers ectopic renal
Fgf23 expression. First, we investigated the effect of hypoxia and the inflammatory cy-
tokine Tnfα on bone cell culture. Hypoxia did not affect Fgf23 mRNA expression neither
in primary mouse osteoblast nor in MC3T3-E1 mouse preosteoblast cells. The inflamma-
tory cytokine Tnfα increased Fgf23 as well as Nurr1 mRNA expression in primary mouse
osteocyts. We proved that kidneys of Pkd1fl/fl, cre+ were inflamed by showing increased
Tnfα and Tgfβ expression levels as well as increased phosporylation of the NfκB p65 sub-
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unit. Likely, Tnfα is responsible for the increased expression of the orphan nuclear receptor
Nurr1 in PKD kidneys. Nurr1 showed predominantly a nuclear localization in cystic kid-
neys whereas it was distributed in the cytoplasm of healthy kidneys. The neutralization
of Tnfα with antibodies reduced Fgf23 plasma levels in PKD and healthy animals and de-
creased the expression of inflammation markers in cystic kidneys. Furthermore application
of anti-Tnfα antibodies tended to lower renal Fgf23 and Nurr1 expression. These results
suggest that the inflammatory cytokine Tnfα affects Fgf23 expression in cystic kidneys as
well as in osteocytes. These findings may have also implications for other forms of CKD
where elevated FGF23 an local inflammation are commonly occurring.
5.1 Limitations
In the first experimental study we used the Han:SPRD rat model which is not the ortho-
logue model of human ADPKD disease. However, Han:SPRD cy/+ rats reproduce the
clinical finding of elevated FGF23 levels when renal function is still normal. This may
be a hint that not the defective Pkd1 gene itself causes the abnormality but rather the
circumstance of cyst growth. We are not able to explain the resistance in Han:SPRD rats
against the highly elevated Fgf23 levels in the presence of normal renal function. It might
be that we missed an early decline in renal function due to hyperfiltration of the remain-
ing nephrons and therefore overestimated creatinine clearence of PKD kidneys. An other
possibility is that Fgf23 which is expressed in response to inflammatory stimuli has an
other function than the well-known regulation of phosphate and vitamin D3 metabolism.
The Pkd1 conditional KO mouse is the orthologue model of human ADPKD. Cre recom-
binase is driven by the beta actin promoter which leads to the Pkd1 gene ablation in the
whole body including bone. Pc1 plays an important role in mechanosensing in bone and
it is unknown if Pc1 signaling itself has an impact on Fgf23 expression in bone. Kidney
specific Pkd1 conditional animals would be useful to shed light on this aspect. Such an-
imals have been obtained during the course of the PhD project but due to limitations of
time could not be investigated to date.
The final evidence that Nurr1 is involved in the Tnfα dependent Fgf23 expression would
need further experiments which involve the downregulation of Nurr1 with siRNA or shRNA
in vitro or application of a Nurr1 antagonist in vivo. To my knowledge there is no Nurr1
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antagonist available so far. Our results regarding the regulation of Fgf23 in osteocytes are
only based on mRNA data, western blot analysis should prove if similar processes happen
on protein levels.
5.2 Outlook
In the near future, the role of Nurr1 in the regulation of Tnfα dependent Fgf23 expression
should be clarified. This could be done in vitro by using siRNA for Nurr1 knockdown.
Nurr1 forms heterodimers with RXR to exert its effect on the regulation of gene expres-
sion. Due to the lack of Nurr1 antagonists, a RXR inhibitor may repress as well the effect
of Nurr1 on gene expression. A more straight forward but also more time consuming
approach would be to use a kidney specific Nurr1 conditional KO mouse. Further, the
events happening in the primary osteocyte cells upon Tnfα stimulation should be analyzed
at the protein levels. The initial decline of Klotho levels in CKD might be triggered by
abnormal cytokine production and therefore Klotho is a factor which has to be considered
in the Tnfα dependent Fgf23 regulation. The analysis of Klotho protein expression in
anti-TNFα treated animals will shed light on this aspect.
In the distant future, it would be interesting to identify and characterize the cells express-
ing Fgf23 in the kidney as well as to identify the steps leading to the transformation of
kidney cells to Fgf23 producing cells. One possibility is that the process of epithelial-
mesenchymal transition (EMT) is involved in this event. Further, it would be interesting
to analyze the Tnfα dependent Fgf23 expression in other CKD models as well as in models
of inflammatory diseases to get an idea about the physiological role of Fgf23 in inflam-
matory processes. Finally, the relevance of TNFα induced FGF23 expression in human
CKD patients has to be clarified. For this purpose the treatment of CKD patients with
TNFα antibodies such as infliximab or etanercept would be one possibility to investigate
the effect of TNFα on FGF23 expression in different forms of CKD.
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